Government Of India Directorate General Of Health Services Govt. Medical Store Depot 9, Clyde Row, Hastings, Kolkata- 700022 Ph.-033-22230409/0542 Fax-033- 22230838 Mail: gmsdkol-mohfw.nic.in
Tender For Generic Drugs
TENDER REFERENCE No:GMSD/KOL/Generic-01
Medical Store Organization, DGHS, (hereinafter referred as Tenders Inviting Authority unless the context otherwise requires) invites Bids for Supply of Generic Drugs as enclosed in Annexure- K for a period of Two Years from the date of conclusion of Rate contract .
The bidder may participate as per his eligibility and have to submit required documents and bids for each of the drug separately. The bids are required to be submitted physically (not online) in the tender box kept for this purpose at Govt. Medical Store Depot, 9, Clyde Row, Hastings, Kolkata- 700022 for which she/he wishes to quote/ apply. 1. Bidding Schedule
Date of Issue/Publishing of Tender Date:06-04-2015 Website: https://eprocure.gov.in http://msotransparent.nic.in Start Date and time for downloading tender documents Time:10.00AM Date:06-04-2015
Last date and time for downloading tender documents and Time:5:00PM Date:14-05-2015 submission of bids
Last Date and Time for submission of Bid ( Three sealed Time:5:30PM Date:14-05-2015 Covers kept in outer single envelope) in office of Sr. C.M.O (SAG) & I/C, Govt. Medical Store Depot, 9, Clyde Row, Hastings, Kolkata- 700022 Date and time of opening Technical Bids Time:11:00AM Date:15-05-2015 Amount of EMD Deposit: As specified in Instructions to the bidders(ITB)
Fee For Tender Form As specified in Instructions to the bidders(ITB)
Tender opening venue/ Office of the Sr. Chief Medical Officer (SAG) & I/C, Govt. Medical Store Depot, 9, Clyde Row, Address for Communication Hastings, Kolkata- 700022
Date and Venue of Pre bid meeting and Bidders awareness Date:23-04-2015 /orientation Venue: Govt. Medical Store Depot, 9, Clyde Row, Hastings, Kolkata- 700022
No:GMSD/KOL/Generic-01 1 Instructions for searching of Tender Document on CPP portal
As per the directives of Department of Expenditure, this tender document has been published on the Central Public Procurement Portal (URL: https://eprocure.gov.in).
1) There are various search options built in the CPP Portal, to facilitate bidders to search active tenders by several parameters. These parameters could include Tender ID, organization name, location, date, value, etc. There is also an option of advanced search for tenders, wherein the bidders may combine a number of search parameters such as organization name, form of contract, location, date, other keywords etc. to search for a tender published on the CPP Portal.
2) Once the bidders have selected the tenders they are interested in, they may download the required documents / tender schedules.
3) The bidders can also download the Tender Document form the MSO website “ http://msotransparent.nic.in”
General Instructions to the Bidders
1) Bidder should take into account any corrigendum published on the tender document before submitting their bids.
2) Please go through the tender advertisement and the tender document carefully to understand the documents required to be submitted as part of the bid. Please note the number of covers in which the bid documents have to be submitted, the number of documents – including the names and content of each of the document that need to be submitted. Any deviations from these may lead to rejection of the bid.
3) Tenderers should submit the bid containing following three sealed covers /envelops separately super scribing in the following manner-
(1) Cover “A” - (Fee for Tender Form & Earnest Money Deposit) (2) Cover “B” -(Technical Bid) (3) Cover “C” – (Price Bid) The above three sealed envelopes are to be again put in a single sealed envelope super scribed with the“TenderEnquiryNo……………. Due for opening on ………………….. and Name & address of the Bidder
4) The completed bid in the prescribed manner must be received at the office of Sr. Chief Medical Officer (SAG) & in Charge, Govt. Medical Store Depot, 9, Clyde Row, Hastings, Kolkata-700022 on or before the time and date given for receipt of Bid. Tenders not submitted by the date/time prescribed shall not be opened and returned unopened. It shall be the sole responsibility of the bidder to ensure that their bid is received at the address above on or before specified date and time mentioned.
5) Bidder should prepare the EMD as per the instructions specified Instructions to the Bidders (ITB) in the tender document.
6) A standard format has been provided with the tender document for submission of Price Bid, to be filled by all the bidders Annexure-L. Bidders are requested to note that they should necessarily submit their financial bids in the format provided and no other format is acceptable. Bidders are required to complete the white coloured cells with their respective financial quotes and other details (such as name of the bidder). No other cells should be changed.
No:GMSD/KOL/Generic-01 2 2. Instruction to Bidders (ITB)
(2.1) In the Technical Bids, the bidders are required to submit various documents in five sets /volumes.
(2.2) The parties to the contract, which shall be deemed to be “Price Agreement “ and which is intended for the supply of stores of the description set forth in the schedule to the Tender during the period specified shall be contractor of the first part and purchaser(s) name in the schedule of the Tender of second part.
No guarantee can be given as to the number or quantity of the stores which will be ordered during the period of price agreement which is in the nature of standing offer only from the contractor, but the purchaser(s) undertake(s) to order from the contractor all stores as detailed in the schedule of stores and prices which he / they require(s) to purchase except that he / they reserve(s) the right.
2.2.1 Of submitting to competition any supply of articles included in the contract, the total value of which exceeds such amount as Secretary (whose decision shall be final) may determine upon consideration of Tenders. 2.2.4 Of placing this price agreement simultaneously or at any time during its period with one or more contracts as /they thinks fit, and 2.2.5 Of obtaining from sources any stores referred to in the contract to meet emergency, if the Secretary (whose decision shall be final) is satisfied that the contractor is not in a position to supply specific quantities or number of days within the period in which supply is required.
(2.3) The Price Agreement in respect of quality procurement shall be governed by the provisions contained in the Drugs and Cosmetics Act, 1940 as amended up to date and the Drugs and Cosmetics Rules, 1945 as amended up to date.
(2.4) GMSDs accept the drugs only from the manufacturing units registered with Medical Store Organisation. However unregistered manufacturers can also submit their bids and simultaneously apply for registration of their manufacturing units with Medical Store Organisation. In case manufacturer fails to get their manufacturing unit registered with Medical Store Organisation, no supply will be accepted from them even if they are successful bidders as L1 in the Price Bid.
(2.5) Fee For Tender Form : Every Bidder will be required to submit Fee for Tender form of Rs. 1000/- in the form of demand draft / bankers cheque drawn in favour of The Sr.Accounts Officer,P.A.O, Min of H&FW, Kolkata in Cover “A” (Fee for Tender Form and Earnest money Deposit).
(2.6) Earnest Money Deposit:
(i) In the Tender Document where estimated withdrawal is indicated in the Schedule of Requirements-the amount of EMD shall be as indicated against each drug mentioned in Annexure-K in the tender document. The total amount of EMD to be submitted by the bidder will depend on the number of items for which the bidder is quoting the rates. The total EMD amount shall be cumulative value of EMD amount indicated in Annexure-K for the drugs for which the bidder is quoting the rates. (ii) In the Tender Document where estimated withdrawal is not indicated in the Schedule of Requirements-the amount of EMD shall be a fixed amount of Rs1,00,000(Rupees One Lakh only )for all the items in the Schedule of Requirements of Tender. EMD should be submitted in the form of Account Payee Demand Draft, fixed Deposit Receipt, Banker‟s Cheque or Bank Guarantee from any of the commercial banks in an acceptable form. ( The Bank Guarantee should be in Favour of Sr. Chief Medical Officer (SAG) & in Charge, Govt. Medical Store Depot, 9, Clyde Row, Hastings, Kolkata-700022 and Account Payee Demand Draft, fixed Deposit Receipt, Banker‟s Cheque in the favour of “The Sr.Accounts Officer, P.A.O, Min of H&FW, Kolkata” )
No:GMSD/KOL/Generic-01 3 (a) The validity of the Earnest money deposit should be 60 days beyond the final bid validity period.
(b) In case the Bidders withdraws his bid within its validity or fail to deposit performance security within specified time after award of contract, the Earnest Money will be forfeited or the firm will be debarred /de-registered for a period of five years.
(c) The bid security of the unsuccessful bidders will be returned to them after expiry of the final bid validity and latest on or before one month after the award of the contract /Supply Order.
(2.7) Firm registered with NSIC etc. will be exempted for earnest money as per Prevailing rules. SSI Units registered with NSIC should furnish a photocopy of the Registration certificate indicating the items for which they are registered.
Bids not accompanied by Cover “A” containing Fee For Tender Form and Earnest Money Deposit or Copy of NSIC Registration Certificate (in case firm is registered with NSIC) will be rejected.
(2.8) Performance Security Deposit
Successful Bidder/ Contractor will have to furnish a Performance Security Deposit with the purchaser equivalent of 5% of the order received from the demanding officer/Purchaser in the form of bank guarantee or in the form of demand draft. The Demand draft should be drawn in favour of “The Accounts Officer of direct demanding officer /Purchaser and the bank guarantee should be in favour of direct demanding officer /Purchaser valid for a period of 60 days beyond the date of completion of all contractual obligations of the supplier, including warranty obligations.
(2.9) Demand Draft finally accepted as Earnest Money Deposit / Performance Security Deposit would be credited to Govt. Account under proper Head of Account.
(2.10) Govt. will not pay any interest on Earnest Money Deposit / Performance Security Deposit, which would stand, credited to Govt. Accounts. Earnest Money would be returned, to unsuccessful Bidder without any interest whatsoever, after conclusion of the contract with successful Bidders. The Earnest money Deposit submitted by the successful Bidder will be returned after successful completion or expiry of the Contract.
(2.11) Performance Security Deposit will be returned to the Bidder after a period of 60 days beyond the date of completion of all contractual obligations of the supplier, including warranty obligations by the depots or Medical Stores Organisation.
(2.12) If the contractor fails or neglects to observe or perform any of his obligations under the contract, it shall be lawful for the purchaser to forfeit the Earnest Money Deposit / Performance Security Deposit furnished by the contractor.
(2.13) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and the Tender Inviting Authority may request the Bidders to extend the bid validity. If the Bidder refuses the extension of bid validity then his Bid will be rejected without forfeiting the Earnest Money deposit.
(2.14) Bidder should note the period for which the offers should remain open for acceptance. The offers from those firms, who have not kept the validity open till the period stipulated in the Tender enquiry, will be treated as non-responsive and will be ignored without making any back reference. Where any firm keeps the offer valid till the required date as stipulated in the Tender enquiry but at the same time gives a discount clause for shorter validity such discount will be summarily ignored and such offers will be considered only in respect of the price quoted by them for full validity. Bidders may further note that in the absence of any indication of the date up to which the offer has, been kept valid it will be assumed that their offer will remain open for
No:GMSD/KOL/Generic-01 4 acceptance for the period Specified in the schedule to Tender enquiry. It may further be noted that if the date up to which the offer is to remain open being or is declared a closed holiday for the Government offices, the offer shall remain open for acceptance till the next working day.
(2.15) All procurement of medicines supplied should be Bar Coded. The details of Bar Coding to be done is given at Clause 19 “Barcoding” of the Tender Document.
(2.16) Attested copies of the following documents should necessarily be submitted with the quotation, in cover “B”( Technical Bid)failing which the Tender will be summarily rejected: -
(2.16.1) Valid Drugs Manufacturing License for which they are licensed to manufacture, indicating each of the items for which Tender is submitted. If the drug- manufacturing license is under renewal, the date of submission of the application for renewal of License and the certificate & challan thereof by the Licensing Authority.
(2.16.2) Good Manufacturing Practices (GMP/ WHO GMP/CoPP) Certificate from the Licensing Authority under Drugs & Cosmetic Act for items quoted in proper form.
(2.16.3) Copy of PAN Card, Registration certificate with VAT and latest VAT return.
(2.16.4) Documentary evidence in Support of Assessed/Installed capacity/Import Quantum details
(2.16.5) Audited financial statement (balance sheet and profit & loss account statement) for the last three years along with annual turnover statements for formulations for the above three years certified by the Auditor.
(2.17) Each page of the quotation must be signed and unsigned quotations will be summarily rejected.
(2.18) The purchaser reserves the option to give purchase preference to the offers from the Central Public Sector undertakings etc. over those offers from other large scale units in accordance with the policies of the Government from time to time.
(2.19) Samples against this Tender inquiry if called for shall be furnished by the date stipulated. Failure to do so will entail the quotation being ignored.
(2.20) Quotations qualified by vague and indefinite expression such as "Immediate Acceptance” "subject to prior sale" etc. will not be considered. Request for advance payment whatsoever will not be considered. Telegraphic / Letter Head/Fax Quotations without complete Tender Documents shall be summarily ignored.
(2.21) Withdrawal of any rates after opening of the Tenders will render the, entire offer invalid and also may involve administrative action against the Bidders.
(2.22) No deviation in specifications and/or nomenclature of stores will be considered. Packing specifications mentioned in the Tender Document must be strictly adhered to.
(2.23) The firms / manufacturer who interested to participate in the Contract should ensure that they fulfill all the eligibility criteria as prescribed in the Tender Documents; otherwise the tenders will be summarily rejected.
(2.24) The Price Agreement will be governed by the terms and conditions of the Tender Document and no modifications / alterations etc. are allowed in any case.
No:GMSD/KOL/Generic-01 5 (2.25) The firms may submit their bids if the terms and conditions as prescribed are acceptable to the bidders andthey fulfill all the eligibility criteria. Therefore bidders are advised to read Terms and conditions and Instructions of Bid Documents carefully before submitting their quotations.
(2.26) 100% Payment on finalization of contractor bills (on the prescribed form )duly supported by original inspection note, original supply order, Supplier Commercial Invoice, ECS mandate form, Bank Details form (duly attested by the banker of supplier) etc. Demand for advance payment will not be admissible.
(2.27) If firm is deregistered / debarred for the supply of item after issue of Tender enquiry for any particular item offers for such item will not be considered.
(2.28) No material assistance whatsoever will be provided by the purchaser.
(2.29) All Tender documents attached with the invitation to Tender are Sacrosanct for considering any offer as a complete offer.
3. Eligibility Criteria (3.1) Bidder shall be manufacturer having valid own manufacturing license/loan license and direct importer holding valid import license are eligible to participate in the tender. However manufacturer having their own manufacturing/ loan license can also submit bid for item manufactured on third party basis, where there is marketing agency agreement as per the enclosed format (Annexure-J) & bidder undertake to abide & own all responsibility including quality of drugs. A letter from original manufacturer should also be submitted that he is not marketing the product directly in India.
(3.2) Bidder should have valid WHO GMP Certificate or CoPP (Certificate of Pharmaceutical Product) from the concerned licensing Authority in case of imported product.
Bidder should have valid GMP Certificate under Schedule „M‟ of Drugs & Cosmetic Act on the date of bid opening for the category of products manufactured in India.
(3.3) Bidder should have at least 3 years (36 months) manufacturing & marketing experience of the particular item as a manufacturer / importer/Loan license/third party manufacturing for each drug quoted in the tender. This would not apply to drugs, which were introduced in India less than 3 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.
(3.4)The drugs to be procured has been classified in two categories Group A and Group B.
The Group A includes essential drugs like drugs acting on Central Nervous System, Cardio Vascular System, Endocrine System, Anti-cancer & Higher Antibiotics and Group B includes rest of the drugs not covered under Group A.
3.4.1 Pharmaceutical firm having minimum annual turnover of Rs. 100/- Crore in each of the last three years will be eligible to quote bid for drugs included in Group „A‟. Pharmaceutical firm having minimum annual turnover of Rs. 50/- Crore in each of the last three years will be eligible to quote bid for drugs included in Group „B‟. 3.4.2 Not less than 50% of Annual Turnover should be from trade i.e. outside institution/ Govt. supplies 3.4.3 The bidder should be marketing quoted drugs at least in all cities where CGHS/GMSD are located. 3.4.4 The bidders during last one year should have manufactured and marketed the quantity of the drug more than the estimated withdrawal indicated in the tender document for the quoted drug. Bidder has to give undertaking for 3.4.2, 3.4.3. & 3.4.4
No:GMSD/KOL/Generic-01 6 (3.5) In case of group A drugs - The manufacturing firm should have their own R&D facilities where they are conducting at least routine testing, stability profile, quality assurance etc. of drug being manufactured. A certificate to this effect signed by Head of their quality Assurance department to be furnished with bid.
4. Preparation of Bids (4.1) The Item(s) as per Tender enquiry should be clearly marked and highlighted in the GMP / Drug Manufacturing or Import License / manufacturing and marketing certificate documents submitted. BIDs will be evaluated separately for each item.
(4.2) The bidders are required to submit Fee For Tender Form and Earnest Money Deposit or Copy of NSIC Registration Certificate (in case firm is registered with NSIC) in a separate sealed Cover “A”
(4.3) The bidders are required to submit various documents in Technical bid, as listed in Clause 5 Technical Bid Cover-B” (from 5.1 to 5.26).The bidders are advised to arrange all the documents in Volume-I, Volume-II, Volume-III, Volume-IV and Volume-V in the same order as they are listed in Clause 5.of theTender Document. All these pages of Volume-I, Volume-II, Volume-III, Volume-IV and Volume-V may be serially numbered and signed with stamp before they are submitted in the Technical Bid.
(4.4) The documents listed from clause no 5.1 to 5.16 are to be submitted as Volume-I documents of the Technical Bids under this Tender
(4.5) The documents listed from clause no 5.17 to 5.21 are to be submitted as Volume-II documents of the Technical Bids which are specific to the drugs under this Tender
(4.6) The documents listed from clause no 5.22 and 5.24 are to be submitted as Volume-III documents of the Technical Bids which are specific to the drugs under this Tender
(4.7) The documents listed from clause no 5.25 and 5.26 are to be submitted as Volume-IV documents of the Technical Bids which are specific to the drugs under this Tender
(4.8) In volume-V only one document is to be submitted i.e. duly filled Annexure B after filling the column no 6 to16 of the Annexure with the relevant information/page number of the respective volume (example Volume……..(page no…))
(4.9) All documents(Volume-I ,Volume-II ,Volume-III and Volume-IV documents) required in the tender should be serially numbered and duly signed by the bidder with the rubber stamp of the firm on each page in chronological order of the checklist enclosed at Annexure-G1, G2,G3 and G4, before submitting.
(4.10) The purchaser may demand to see the original document or submission of attested /certified copy of any document which has been submitted or other document(s) requiring clarification.
(4.11) All the information called for in all the BID documents should be answered, failing which, the bid shall not be considered and is liable to be rejected without any further reference. (4.12) The purchaser reserves the option to give a purchase/ price preference to the offers from public sector units etc., in accordance with the policies of the Govt. of India from time to time.
(4.13) The Bidders should not reveal their rate quotation in Technical Bid (Cover “B”) in any manner otherwise the bid will summarily rejected. 5. Technical Bid -Cover-“B”. All documents required in the tender to be submitted as volume-I , volume-II, volume-III and volume-IV documents should be serially numbered and duly signed by the bidder with the rubber stamp of the firm on
No:GMSD/KOL/Generic-01 7 each page in chronological order of the checklist enclosed at Annexure-G1,G2,G3 and G4, before submitting. This should interalia include the following certificates / documents for the items to be submitted.
The Tender shall be liable to be rejected if following documents are not submitted with the Technical BID
Volume -I ( Documents as per check list - Annexure G1) to be submitted
(5.1) Duly filled, signed & stamped of Check list of documents submitted in volume-I of documents –AnnexureG1
(5.2) Forwarding Letter of the Firm
(5.3) Self attested copy of notarised power of attorney. The bidder shall sign the bid or a person duly authorised to bind the bidder to the contract. The authorised signatory should have power of attorney from the Proprietor / Partners of the firm/ MD / Chairman / President duly attested and signed by Notary Public.
(5.4) Letter of Undertaking as per Annexure-A
(5.5) Audited financial statement (balance sheet and profit & loss account statement only) for the last three Years along with annual turnover statements for formulations for the last three years duly certified by the Auditor / chartered accountant.
(5.6) Declaration duly certified by the Chartered Accountant (CA) that the manufacturer/bidder has not less than 50% of Annual Turnover from outside the institution/Govt.
(5.7) Name and address of banker /bankers
(5.8) Copy of PAN Card, Registration certificate with VAT and latest VAT
(5.9) Additional Questionnaire for Price Agreement / Rate Contract Enquiries as per Annexure- H
(5.10) Non-conviction certificate for three continuous years from the Licensing Authority/Drug Controller of the concerned States
(5.11) The General & Financial information and declaration duly filled as per Annexure-E
(5.12) Certificate regarding de-registration/ debarred / blacklisted / banning / suspended for business etc. as per Annexure-F (5.13) Copy of Manufacture Agency Agreement as per Annexure-J in case of third party manufacturing in India, if applicable
(5.14) Undertaking that the bidder is marketing quoted drugs at least in all cities where CGHS/GMSD are located. (5.15) Certificate signed by Head of their quality Assurance department (for Group ‘A’ drugs only ) that manufacturing firm have their own R&D facilities where they are conducting at least routine testing, stability profile, quality assurance etc. of drug being manufactured
(5.16) Certificate that bidder have manufactured and marketed/Imported and marketed not less than the quantity indicated in the bid for the quoted drug during last one year in case estimated drawal is indicated in Annexure K. Volume -II ( Documents as per check list - Annexure G2) to be submitted (5.17) Duly filled, signed & stamped of Check list of documents submitted in volume- II of documents - Annexure-G2
No:GMSD/KOL/Generic-01 8 (5.18) Valid Drug Manufacturing /Import License with its validity. If revalidation of drug license has been applied for the copy of application to State Drug / Licensing authority may be attached with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by licensing authority and Certificate of approval of Drug Controller General of India for new drugs if any.
(5.19) Valid GMP or WHO GMP or CoPP (Certificate of Pharmaceutical Product) Certificate from the concerned licensing Authority for the category of product for which rate is being quoted.
(5.20) Copy of Certificate of original manufacturer of product from the State Drug Controller if any.
(5.21) Copy of Certificate of sole manufacturer of product from State Drugs Controller if any.
Volume -III ( Documents as per check list - Annexure G3) to be submitted
(5.22) Duly filled, signed & stamped of Check list of documents submitted in volume-III of documents – Annexure-G3
(5.23) Certificate in the prescribed proforma as per Annexure- C from the Manufacturers/bidder or Chartered Accountant regarding three years (36 months) manufacturing/importing and marketing experience of the particular item and for all strengths. The Certificate must have been issued within past six month from the date of opening of Tender and not more than one year old on the date of opening of Tender. In the case of direct importer, evidence for importing the quoted item for last three years (36 months) will be produced.
(5.24) Data to establish his production/import capacity as per certificate Annexure-D
Volume -IV ( Documents as per check list - Annexure G4) to be submitted
(5.25) Duly filled , signed & stamped of Check list of documents submitted in volume-IV of documents - Annexure G4
(5.26) Copies of the Labels of primary and secondary packing of the products for which the offer is beingmade should also be submitted.
Volume -V Duly filled Annexure B to be submitted
In Volume-V only one document is to be submitted after filling the column no 6 to 16 of the Annexure with the relevant information/page number
6. Price BID-Cover-“C” The price bid will also be known as financial document and every bidder will be required to submit its price in format attached to the tender document Annexure-L.
7. Opening of Technical and Financial Bid of Tender The Technical Bids of the respective tender will be opened as per the bidding schedule under clause 1 of the tender document. The Technical bids will be scrutinized by the respective Technical Evaluation Committee.
Those Bidders whose bids found responsive on satisfying the criteria for technical evaluation will only be eligible to be present at the date and time for opening of Price Bid. The Date and time of opening of the
No:GMSD/KOL/Generic-01 9 Price Bid will be announced on the MSO website “http://msotransparent.nic .in after the completion of evaluation of Technical Bids by the Technical Evaluation Committee.
8. Other Terms and Conditions 8.1. PRICES: The price bid will also be known as financial document and every bidder will be required to submit its price in format attached to the tender document. The prices quoted must be net per unit and inclusive of all Taxes, Duties, Levies, Cess, Octroi/Entry Tax, surcharge, freight, loading, unloading, insurance, road permits, packing, etc.
8.1.1 Rates should be quoted on 'FOR Destination' basis or Free Delivery on Door Delivery Basis to all Govt. Medical Store Depots located at Kolkata, Chennai, Guwahati, Hyderabad, Karnal, Mumbai and New Delhi and all units of CGHS. All the transit loss whatsoever will be borne by the supplier firm (any monetary limit is not acceptable). Uniform rates for all the depots and CGHS units must be quoted. Quotations at different rates for different depots/CGHS units will not be considered. The goods are to be supplied F.O.R. destination or free delivery on door delivery basis to all depots and CGHS Units.
8.1.2 Rate quoted for packing other than required specified packing will not be considered and shall be summarily ignored. 8.1.3 No conditional offer / discounts for early delivery / payment etc will be accepted. Any conditional price /rate quote (except where quotes are called on variable price basis) shall render the financial BID disqualified on ground of conditionality.
8.1.4 The prices quoted by the Bidders should be on firm and fixed basis during the currency of the rate approval. However in respect of such drugs where prices are governed by Essential Commodities Act 1955 and Drugs Price Control Order 2013, the prices quoted should not exceed the ceiling price of DPCO/NPPA
8.1.5 The price quoted by the Bidder should be less than the price obtained by them from the trade and actual. 8.1.6 the purchaser also reserve the rights (1) to enter into parallel Price Agreement(s) simultaneously or at any time during the period of the Price Agreement with one or more Bidder(s) as purchaser think fit and (2) to place adhoc contract or contracts simultaneously or at any time during the period of this contract with one or more supplier(s) / Tenders(s) for such quantity of such item or items as the purchaser (whose decision shall be final) may determine. 8.1.7 The purchaser‟s reserves the right to accept in part or in full any Tender or reject any Tender without assigning any reason or to cancel the E-Tendering process and reject all Tenders at any time prior to award of contract, without incurring any liability whatsoever to the affected Tendered or Bidders.
8.1.8 If the above instructions and other Tender Terms & Conditions are not adhered to by the Bidder, the quotation may summarily be rejected and the Medical Stores Organisation will not be liable to answer for the same.
9) Tolerance Clause (applicable in case fixed quantity is specified in Tender Document) (a) At the time of awarding the contract, the purchaser reserves the right to increase or decrease by up to twenty five (25) per cent, the quantity of goods and services if mentioned in the schedule(s) in the “List of Requirements” (rounded off to next whole number) without any change in the unit price and other terms & conditions quoted by the Bidder.
No:GMSD/KOL/Generic-01 10 (b) If the quantity has not been increased at the time of the awarding the contract, the purchaser reserves the right to increase by up to twenty five (25) per cent, the quantity of goods and services mentioned in the contract (rounded off to next whole number) without any change in the unit price and other terms and conditions mentioned in the contract, during the currency of the contract frame. 10. Delivery Period and Delivery of stores: 10.1 The date of delivery of stores stipulated in the supply order shall be deemed to be the essence of the contract and delivery must be completed within stipulated Date of Delivery which is normally 60 days for item manufactured in India
10.2 If the supplier feels he cannot supply the items during the validity period of supply order, he should apply for extension of period giving valid justification before the last date of delivery. Extension can be granted by procurement agency if they are satisfied that supplier would come forward during the extended period with a penalty @1% of the delivered price of the delayed goods for each week of delay or part thereof, until actual delivery up to a maximum deduction of 5 percent of the delayed goods contract price. Once the maximum is reached, the purchaser may consider termination of the contract.
10.3 If firm is under the process of deregistration / debarment for supply of any drug due any event of failure of the drug in laboratory test and show cause notice has been issued as per the Inspection and Tests Clause, then all orders already placed by demanding officer up to the date of order coming in to force shall be executed by the firm during delivery period specified in such contract. No extension of delivery period in such contract shall be considered.
10.4 If firm is deregistered / debarred for the supply of the item /blacklisted banned during the currency of agreement all orders already placed by demanding officer up to the date of order coming in to force shall be executed by the firm during delivery period specified in such contract. No extension of delivery period in such contract shall be considered
11. The terms & conditions for supply orders placed by CMO In-Charges of CGHS wellness centre on monthly requirement basis.
a) The delivery period shall be 20 days from the date of issue of order. b) Before actual delivery of the drugs you should inform the CMO I/C of wellness Centre, the date of delivery of material. The Wellness Centre working hours is 8.00 AM to 3.00 PM from Monday to Saturday. c) The supply should be tendered for minimum number of batches for each lot. d) Certificate of Analysis (COA) should be submitted to paying authority along with the bill & a certificate to this effect should be written on the body of voucher submitted to dispensary.
e) At time of supply, shelf life of Drug should not have passed more than 1/4th of the effective shelf life of drugs.
“ In case of imported drugs at the time of supply the remaining shelf life should not be less than 75% of the effective shelf life of drugs. However on case to case basis the lower shelf life if permissible under the Drugs & Cosmetics Act and rules made there under subject to the furnishing their undertaking that if any quantity remains unconsumed, the same shall be replaced or the cost of the same shall be refunded”.
No:GMSD/KOL/Generic-01 11 f) If there is delay in the supply, the quantity should not be carry forward to the next month requirement unless demanded in the next month indent.
g) All supplies should be duly bar coded & marked as “CGHS SUPPLY NOT FOR SALE”.
h) Payment shall be made on the basis of receipt of all bill submitted in favor of CGHS (MSD), along with original copies of receipt voucher duly signed & stamped by CMO In-Charges of the Wellness Centre, copies of certificate of analysis. 12. Period of Price Agreement.
(i) The price Agreement shall be operative for a period of Two year from the date of Conclusion of Rate contract with the condition that in case if there is a fall in the institutional price due to reduction in cost of raw material, custom duty exemption etc. the manufacturer will have to reduce the price proportionately. The successful Bidder shall note that supply orders may be placed up to the last day of the currency of the Price Agreement. (ii) Whenever any Purchase Order is placed during the validity of the contract it shall be binding on the firm to supply it as per Schedule given by the purchaser.
13. Packing and Marking Required
13.1.PACKING FOR TABLETS AND CAPSULES.
(a) INITIAL PACKING
(i) Unless otherwise specified in Supply Order. Tablets/ Capsules are required to be packed in standard Aluminum /Aluminum Blister. The aluminum strip should be of thickness not less than 0.03mm. The packing material should have compatibility with the tablet, capsules. The manufacturer will submit a self certificate with each consignment specifying thickness of Aluminum Foil.
(ii) Blister /Aluminum strip pack of not more than 140 tabs /caps should be packed in thick cardboard box so that container should provide adequate protection to the drugs. However, manufacturers of items having market packs more than 140 tablets per carton may submit their specifications and proper justification in support of their bigger packing for consideration before supply is made to the consignee Depots. (b) FINAL PACKING. Final packing shall be done in corrugated fiber Board boxes confirming to IS: 2771 (part-I):1990 suitably cushioned lined and strong enough to bear Rail/Road transit hazards. The supplier should furnish a self certificate with each consignment to the effect that packing material is confirming to IS: 2771 (part- I):1990.
13.2. PACKING FOR BOTTLES.
Bottles should confirm the container/content compatibility test.
(a) INITIAL PACKING.
No:GMSD/KOL/Generic-01 12 Initial packing shall be done in single well corrugated fibre board boxes weighing not more than 10 KG confirming to lS2771 (Part-I) 1990 suitably nested and strong enough to bear the Rail/Road Transit Hazards.
(b) FINAL PACKING.
Final packing shall be done in 7-ply corrugated fiber Board Boxes weighing not more than 20 Kgs conforming to lS/277l/Part-I: 1990 suitable Cushioned lined and strong enough to bear the Rail/Road Transit Hazards. The supplier should furnish a self certificate with each consignment to the effect that packing material is confirming to IS: 2771 (part-I):1990
13.3. PACKING FOR INJECTION Vial/Ampoules should confirm the container/content compatibility test.
(a) INITIAL PACKING In neutral plain glass ampoule/ vial confirming to IS:1984 (Part-I) 1971 for relevant capacity provided with rubber stopper and pilfer proof metallic seal(in case of vials) and enclosed in strong card board carton and 25/50 vials/ampoules enclosed in well cushioned nested card board carton.
(b) FINAL PACKING Final packing shall be done in corrugated fiber board boxes confirming to IS: 2771(Part4):1990 suitable Cushing and liner and strong enough to bear the Rail/Road transit hazards. The supplier should furnish a self certificate with each consignment to the effect that packing material is confirming to IS: 2771 (part-I):1990.
13.4. PACKING INSTRUCTION FOR IV FLUIDS (a) INITIAL PACKING PVC bottles should confirm the container/content compatibility test for the contents of the container and should be manufactured by Form Fill Seal (FFS) Technology of relevant capacity as indicated in the List of Drugs (Annexure-B).
(b) FINAL PACKING Final packing shall be done in corrugated fiber cardboard carton (7ply only) confirming to lS: 2771 (Part-I):1990 duly nested containing not more than 25 bottles. The supplier should furnish a self certificate with each consignment to the effect that packing material is confirming to IS: 2771 (part- I):1990
13.5. Packing of each drug item should be strictly according to the requirements specified in the list of each category of drugs and or as indicated in the Tender enquiry in detail.
13.6. The package will indicate the name of the manufacturer, the date of manufacture, date of expiry and the batch no. The labels both on Innermost packing and outer Containers should be marked with the words "CG SUPPLY NOT FOR SALE" in bold red letters
13.7 Labeling and packing shall be as per the provisions contained in the Drugs and Cosmetics Rules 1945 as amended up-to-date, other particulars of labeling, if any, prescribed by the Direct Demanding Officer in his supply order should be complied with.
No:GMSD/KOL/Generic-01 13 13.8. The supplier shall provide such packing of the goods as is required to prevent their damage or deterioration during transit to their final destination as indicated in the contract. The packing shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, sunlight and humidity during transit and storage. Packing case size and weights shall take into consideration, where applicable, the remoteness of the Goods' final destination. All primary packaging containers, which come in contact with the pharmaceuticals or drug content, shall strictly conform to the specifications in the relevant pharmacopoeia to protect the quality and integrity of the goods.
13.9. Offers with packing not in terms of the requirement of Tender enquiry shall be summarily ignored.
14. Shelf Life 14.1 Minimum shelf life of the drugs offered should be as mentioned in months against each item in the Annexure –B to be submitted in Technical Bid. .
14.2 The Bidder should note that at the time when the stores are offered for inspection, the life of the drugs shall not have passed more than one sixth (1/6th) of the effective/useful life of the drug counted from the date of manufacture. Loss or premature deterioration due to biological and other activities during the life potency of the drugs shall have to be made good by the contractor free of cost or shall have to refund the cost of substandard drug lying with depot or at the indentors end.
In case of imported drugs at the time of supply the remaining shelf life should not be less than 75% of the effective shelf life of drugs. However on case to case basis the lower shelf life if permissible under the Drugs & Cosmetics Act and rules made their under subject to the furnishing their undertaking that if any quantity remains unconsumed, the same shall be replaced or the cost of the same shall be refunded.
15. Warranty 15.1. Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeial standards.
15.2. Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under: "The Contractor/Seller hereby declares that the stores as detailed below sold to the purchaser under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned in the description clause here of and the contractor/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the purchaser ,, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Not withstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the purchaser, in that behalf is final and conclusive, the purchaser will be entitled to reject the said stores or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee‟s site.
On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The Contractor/Seller shall if so called upon to do so by the purchaser in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such
No:GMSD/KOL/Generic-01 14 further period as may be extended from time to time by the purchaser at his discretion, on application made there under by the contractor/Seller after the stores or such portion of the stores thereof as is rejected by the purchaser and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the contractor/seller shall pay to the purchaser such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the purchaser in that behalf under this contract or otherwise".
SO No. & Nomenclature & Batch No. DOM & DOE Qty. of Remarks
Date Specification each batch
Signature name & designation and date with rubber stamp.
15.3. If the supplier, having been notified, fails to replace within the period specified above, the purchaser may proceed to take such remedial action as may be necessary at the suppliers' risk and expense and without prejudice to other rights which the purchaser may have against the supplier under the contract.
16. Recalls If products must be recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the purchaser, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund if the product has been taken off the market due to safety problems.
17. Annual Estimated Drawals The annual value of drugs to be ordered by the Department will be dependent on individual requirements of the various drugs including the items in the subject enquiry.
18. Name of authorized officers/offices A) Purchaser : The President of India B) Inspection Authority : DGHS New Delhi & CGHS C) Inspecting Officer : Head of the Depots or their authorized Representative(s) for the respective requirement. D) Place of Inspection : At Consignee Premises / firms premises. E) Paying Authority : Pay & Accounts Officer, Ministry of Health and Family Welfare, of concerned Depots F) Price Agreement : Dte. General of Health Services (Medical Store operating officers Organization), New Delhi and its GMS Depots located at Kolkata, Chennai, Guwahati, Hyderabad Karnal, Mumbai & New Delhi and all units of CGHS
19. Bar Coding
All medicines supplied should be bar-coded as under:
All medicines supplied should incorporate GS 1 bar codes at various packaging levels (primary, secondary and tertiary level packaging) and should encode the information within the barcodes as mentioned below
The GS1 barcode requirements for medicines/drugs at various packaging levels can also be downloaded from the website of Ministry of Health& Family Welfare, Govt. of India at below link:
No:GMSD/KOL/Generic-01 15 http://mohfw.nic.in/gs1_barcode_&_ User_Manuals.htm
GS1 barcode requirements On Medicines/Drugs procured by MSO These requirements cover medicines /drugs procured by Medical Stores Organization (MSO) for both branded & generic pharmaceuticals / drugs. For medical devices & other medical supplies separate GS 1 barcode requirements apply which are available at http://mohfw.nic.in/gs1_barcode_&_User_Manuals.htm
Barcode requirements using GS1 identification standards are provided below at various levels of product packaging which include at primary, secondary and shipper/carton levels and need to be complied with while supplying medicines /drugs to MSO.
Section A) Primary Level Packaging Primary Level Packaging: Is defined as the first level of packaging in direct contact with the product and marked with an AIDC (Automatic Identification and Data Capture) data carrier either on the packaging or on a label affixed to the packaging. It may consist of a single item or group of items for a single therapy such as a Kit. For packaging configurations that include a retail consumer trade item, primary packaging is a packaging level below the retail consumer trade item.
Bar codes using GS 1 standards are required to be marked onto the primary level of packaging encodings 1 product identification code (called GTIN–Global Trade Item Number).Where product is packed in a mono carton (e.g. ointments, eye/ear drops etc),bar code encoding GTIN should be marked on the mono carton itself.
GTINs (Global Trade Item Numbers):It is the GS1 identification key used to uniquely identify each product type/variant. It is created using a GS1 or U.P.C. Company Prefix number. GTIN can be of14 digits(i.e. TIN -14)or13 digits(i.e. GTIN -13)or12digits(i.e .GTIN -12)or8 digits(i.e. GTIN -8) depending on barcode symbology used.
Note: Barcodes using GS1 standards are required to be marked on product packaging in addition to existing statutory labeling & marking requirements. Barcode Symbology: GS1 Data Matrix( two dimensional) symbology is the preferred option.
GS1 Data Matrix symbology can encode product data in much smaller space than what is possible with one dimensional barcode symbology.This is an important consideration in health care sector due to very limited availability of printing space on product packaging, after complying with other statutory labeling & marking requirements.GS1 Data Matrix is thus the preferred option for marking in the health care sector.
Schematic example of GS1 Data Matrix symbology encoding GTIN-14 using Application Identifier (01) at Primary level packaging is as below:
(01)08901107000011
For specs related to GS1 Data Matrix barcode, refer to GS1 general specifications available on http://www.gs1india.org.in/gs1barcodes/pc_index.htm.
Other barcode symbologies (EAN/UPC, GS1–128 andGS1 Data bar) on primary level packaging shall also be acceptable. Details on other GS1 barcode symbologies (EAN/UPC,GS1– 128, ITF-14,GS1Databar),are available at http://www.gs1india.org.in/gs1barcodes/pc_index.htm
No:GMSD/KOL/Generic-01 16 Section B) Secondary Level Packaging
Secondary Level Packaging: Is defined as a level of packaging that may contain one or more primary packages or a group of primary packages containing a single item.
NOTE:There may be additional intermediate packaging levels above the secondary level packaging, but below the Shipper/Carton level packaging. These intermediate packaging levels are not required to be barcoded at this time .Examples of these exclusions includes: Inner packs(bundles) Intermediate packs(inner case) At Secondary level packaging, the barcode should encode the following information:
1) Product identification code (UniqueGTIN-14 of secondary pack)* using application identifier (01) 2) Expiry Date in YYMMDD format using application identifier (17) 3) Batch/Lot Number using application identifier (10) or Serial No using application identifier (21).
*Note: GTIN-14 of secondary level packaging should be different from GTIN-14 of primary and shipper pack. For details on generation of same refer to GS1 General Specifications.
The above barcoding requirements shall be in addition to existing statutory labeling & marking requirements.
Barcode Symbology: Any of the following GS 1 barcode symbologies can be used to encode above stated data in barcodes at Secondary level packaging:- GS1-128,GS1Data Matrix,GS1Data Bar. Examples
a) GS1-128 symbology, encoding GTIN + Expiry Date + Batch/Lot No is represented schematically as below:-
( 01) 08901107000028( 17) 090400( 10) ab12345
b) GS1-128 symbology, encoding GTIN + Expiry Date + Serial No is represented schematically as below:-
( 01) 08901107000028( 17) 090400( 21) 122347842306
Details on other GS1 barcode symbologies at secondary packaging level (GS1 Data matrix and GS1 Data bar) are available athttp://www.gs1india.org.in/gs1barcodes/pc_index.htm
Section C) Shipper/Carton Level Packaging
Shipper/Carton Level Packaging: Is defined as a level of packaging that may contain one or more primary/secondary levels of packaging.
Shippers/cartons can be considered orderable trade items (requires homogeneous pack) AND may also be considered logistics units (heterogeneous packs). The following rules apply to each variation:
No:GMSD/KOL/Generic-01 17 i) The requirements for the orderable trade item (homogeneous pack): The first barcode:
1) Product Identification (Unique GTIN-14 of Shipper pack) using application identifier (01) 2) Expiry Date in YYMMDD format using application identifier (17) 3) Batch/Lot Number using application identifier (10) The second barcode:
a. SSCC (Serial Shipping Container Code) to identify individual carton uniquely using application identifier (00)
Product name : ABCDXYZ Expiry date : 04/09 (April/09) Batch no. : ab12345
( 01) 08901107000035( 17) 090400( 10) ab12345
( 00) 189011070000000018
(Single Label for each carton)
*Note: GTIN-14 of shipper level packaging should be different from GTIN-14 of primary and secondary pack. For details on generation of same, refer to GS1 General Specifications.
Barcode Symbology: GS1-128 and GS1 Data Matrix symbologies can be used to generate the first barcode. The second barcode (SSCC) requires GS1-128.
Human readable information on the label will be as per existing statutory labeling & marking requirements.
ii) The requirements for logistics unit (heterogeneous pack):
If multiple items are packed in a carton / shipper (heterogeneous pack), and / or the shipper / carton level packaging is not an orderable unit, only second barcode should be present (i.e. SSCC).
Human readable information on the label will be as per existing statutory labeling & marking requirements.
No:GMSD/KOL/Generic-01 18 Schematic example of GS1-128 symbology for the logistics unit (heterogeneous pack) encoding above stated data at Shipper/ Carton Level Packaging is as below:
SSCC (Serial Shipping Container Code) to identify individual carton uniquely using application identifier (00)
(Single Label for each carton)
General Notes:
1. While barcoding has been chosen as the automatic identification data capture (AIDC) technology currently, future requirements may demand use of any other data capture technology. 2. Data requirements as stipulated above, take into account minimum level of AIDC marking. MSO however reserves the right to modify the same and direct implementation of higher level of AIDC marking (additional data requirements) in future, in the event of higher perceived risks in line with GS1 General Specifications. 3. Complete details on GS1 standards along with technical guidelines can be downloaded from www.gs1india.org or www.gs1.org 4. For any assistance, you can contact Shri. Swaminathan at 011-26168720/721/725 ,09810441987
No:GMSD/KOL/Generic-01 19 20. Firm Delivery Period Clause
20.1 The Bidders should indicate the guaranteed delivery period for completion of supply from date of placement of individual supply orders, against the Price Agreement with monthly rate of supply against individual items quoted by the Bidder with lead time, if any required by them for commencement of supplies. The contract shall be maintained / at the station / stations indicated by them in the Tender.
20.2 Upon receipt of an order from any officer authorized to place orders, the successful Bidder shall, within seven days intimate, to such officer the quantity which can be supplied within the period stipulated therein and the time required to supply the balance. If the successful Bidders shall fail to give such intimation within the time aforesaid he shall be deemed to have agreed to supply the stores within the delivery date stipulated in the supply order. If the successful Bidders is unable to supply stores or any part thereof within the time specified in the supply order and intimates the time within which the supply order will be made by him the officer placing the supply order will notify his acceptance of the delivery time offered by the contractor or negotiate until an agreement is reached, in all cases, the delivery time as deemed to be accepted by the successful Bidder or agreed upon as aforesaid between him and the officer placing the supply order shall be deemed to be of the essence of the contract and delivery must be completed not later than such date. If in any case no agreement with respect to the delivery time is reached between the contractor and the officer who has issued the supply order, It shall be lawful for such officer to withdraw the supply order, and the contractor shall have no claim in respect of such withdrawals. 21. Delays in the Supplies Performance of the Contract
21.1 Delivery of the stores shall be made by the supplier in accordance with the time scheduled, as per clause10 “Delivery Period and Delivery of stores”above. Any deviation performance of its delivery obligations shall render the supplier liable to any or all of the following action. (a) Forfeiture of its Earnest Money Deposit /Performance Security Deposit and / or (b) Imposition of penalty and/or (c) Termination of the contract for default.
21.1 If at any time during the performance of the contract, the supplier should encounter conditions impending timely delivery of the goods, the supplier shall promptly notify the purchaser in writing of the facts of the delay its likely duration and its clause(s).As soon as practicable after receipt of the suppliers notice, the purchaser shall evaluate the, situation and may at Its discretion extend the suppliers time for performance in which case the extension shall beratifiedbythepartiesbyamendmentofthecontract.Theextensionofthedeliveryperiodwill be subject to the following conditions.
a. The Purchaser shall deduct from the contractor penalty/liquidated damages on the stores under the provision of clause 22 “Penalty Clause for late/non supply” ,which the contractor has failed to deliver within the delivery period fixed for delivery. 22. Penalty Clause for late / non supply
If the supplier feels he cannot supply the items during the validity period of supply order, he should apply for extension of period giving valid justification before the last date of delivery. Extension can be granted by procurement agency if they are satisfied that supplier would come forward during the extended period with a
No:GMSD/KOL/Generic-01 20 penalty @1% of the delivered price of the delayed goods for each week of delay or part thereof, until actual delivery up to a maximum deduction of 5 per cent of the delayed goods contract price. Once the maximum is reached, the purchaser may consider termination of the contract. 23. Termination for Default
The purchaser may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part
a. If the supplier fails to deliver any or all of the goods within the time periods specified in the contract or any extension thereof granted by the purchaser pursuant to clause 21“Delays in the Supplies Performance of the Contract”. Or b If the supplier fails to promptly replace any goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall. c. If the supplier fails to perform any other obligation(s) under the contract.
23.2. In the event, the purchaser terminate the contract in whole or in part, pursuant to above clause 23.1 and without prejudice to the purchaser‟s other remedies, the purchasers may procure upon such terms and in such manner as it deems appropriate, goods or services, similar to those undelivered or unformed, the supplier shall be liable to the purchasers for any excess cost for such similar goods. However, the supplier shall continue performance of the contract to the extent not terminated. 24. Force Majeure
24.1 Notwithstanding provisions of clauses 21, 22 and 23 -“Delays in the Supplies Performance of the Contract”, “Penalty Clause for late / non supply” and Termination for Default” the supplier shall not be liable for forfeiture of its performance security, penalty or termination for default if and to the extent that, its delay in performance or other failure to perform its obligations under the contracts is the result of an event of force majeure.
24.2 For the purpose of this clause, force majeure means an event beyond the control of the supplier and not involving the suppliers fault or negligence and not foreseeable and unanticipated by and not brought about at the instance of the supplier and which has caused the non-performance or delay in performance. Such events may include, but are not restricted to, acts of the purchaser either in its Sovereign or contractual capacity, wars or revolutions, fires, floods, epidemics, quarantine restriction and freight embargoes.
24.3 If a force majeure situation arises, the supplier shall promptly notify the purchaser in writing of such conditions and the cause thereof. Unless otherwise directed by the purchaser in writing the supplier shall continue to perform its obligations under the contract as far as reasonably practical and seek all reasonable alternative means for performance not prevented by the force majeure event. 25. Fall Clause
25.1. The Bidder should confirm acceptance to the fall clause given herein under
25.2 The price charged for the store supplied under the contract by the contractor shall in no event exceed the lowest price at which the contractor sells the stores or offers to sell stores of identical description to any
No:GMSD/KOL/Generic-01 21 persons / organisations including the purchaser or any Department of the Central Government or any Department of a State Government or any statutory Undertaking of the Central or State Government, as the case may be during the period till performance of all supply orders placed during the currency of the Price Agreement is completed. In any subsequent date after submission of the quotation or placing of a supply order, the manufacturer (the term manufacturer will also include his authorised distributor/agent) reduces the sale price of such stores “ In case there is a fall in the institutional price due to reduction in price of raw material, customs duty exemption etc. the manufacturer will have to reduce the price proportionately ” or sells or offers to sell such stores to any other party at a price lowest than the price charged/chargeable against the supply order placed by the Medical Stores Depot, the manufacturer (including his authorised distributor/agent as aforesaid in case the quotation is submitted by them and the supply is also effected by them) Will forth-with notify such reduction in sale price to the officer-in-charge of the Govt. Medical Store Depot and the price payable for the stores to be supplied against the supply order after the date of such reduction in sale price coming into force, shall stand correspondingly reduced.
The above stipulation will, however, not apply to:
(a) Export / Deemed Exports by the Contractor (b) Sale of drugs which have short leftover expiry dates, and (c) Tender submitted in response to fixed quantity contract enquiries issued by MSO.
25.3 Contractor shall submit a certificate to the concerned Pay and Accounts Officer at the time of claiming payment for supplies made against price agreement that stores of description identical to the stores supplied to GMSD(s) under the price agreement have not been offered / sold by them to any persons / organizations up to the date of bill / completion of supply against all supply orders placed at a price lower than the price charged to the purchaser(s) under the price agreement. It is further certified that there is no fall in the institutional price due to reduction in price of raw material, customs duty exemption etc. and in such case, the manufacturer will have to reduce the price proportionately.
26 Inspection and Tests
26.1 The purchaser or its representative shall have the rights to inspect and/or to test the goods to confirm their conformity to the contract technical specifications. The inspection and tests shall be conducted at the manufacturer works and/or at the goods final destination and inspection note will be released on receipt of satisfactory test report. 26.2 Unless otherwise provided for in the contract if the special tests or independent test proves satisfactory and the stores or any installment thereof is accepted, the quantity expended in test will be deemed to have been taken delivery of/by the purchaser and, be paid for as such.
26.3 Rejection and Penalty Clause (A) Rejection -Should any inspected or tested goods fail to conform to the specifications, the purchaser may reject them and the supplier will remove the rejected stores at their cost.
Penalty in the event of failure in laboratory test
(B) In case any item is found substandard either at the inspection stage or during the shelf life of the item, the report of the Government approved laboratory shall be accepted by the firms. If the same is disputed by the firms giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata and the report of CDL will only be accepted as final.
No:GMSD/KOL/Generic-01 22 In the event of drugs supplied found substandard in laboratory test, the following deregistration / debarment action will be taken against the manufacturing unit and contract holding firms
(i) For Category 'B' defects, the manufacturer and contractor will be debarred for supply to MSO of that particular product declared not of standard quality for a period of three (3) years from the date of failure. (ii) In regard to category 'A' defects, the supplier should be debarred for the supply of that product for three years from the date of failure and for repeated failure of category „A‟ defect within one year from previous date of failure, the supplier shall be debarred from supply of all the products for five (5)years.
(C) Category of Defects-The detail of the category-A and category-B defects are given in Annexure-I
(D) In the event of failure of their products, in addition to the debarment /de-registration action, the 5% performance security of the suppliers will be forfeited and the testing charges involved will be recovered by MSO/GMSDs from the supplying firms.
26.4 The purchasers right to inspect, test and, where necessary reject the goods after the goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed by purchaser or its representatives prior to the goods dispatch from the place of manufacture. 26.5 Nothing in clause 26.3 “Rejection and Penalty Clause” shall in any way release the supplier from any warranty or other Obligations under the contract. 26.6 The supplier will be responsible to take back the rejected stores from the depots/consignee place and replace with fresh stock duly inspected within forty five days or as stipulated in the notice issued to the supplier, at their own cost up to the consignees or depots.
26.7 In case of Pre Despatch Inspection, stores will be delivered at consignee‟s side within the validity of the inspection note.
26.8. Non-supply and/or rejection on inspection/test repeatedly will be considered as bad Performance, which would render the Bidders liable to be debarred from participation of the Bidders In future. 27. Transit Insurance
27.1 The depot shall not be responsible for any breakage/leakage/shortage during transit etc.
27.2 Thepurchaserwillnotpayseparatelyfortransitinsuranceandthesupplierwillberesponsibletilltheentirestorescont ractedfor arrive in good condition at destination. 28. Termination for Solvency Thepurchasermayatanytimeterminatethecontractbygivingwrittennoticetothesupplierwithoutcompensationto supplierifthesupplierbecomesabankruptorotherwiseinsolventprovidedthatsuchterminationwillnotprejudiceto affectanyrightofactionorremedywhichhasaccruedorwillaccruethereafter to the purchaser. 29. Laws Governing the Contract
29.1 This contract shall be governed by the laws of India for the time being in force
No:GMSD/KOL/Generic-01 23 29.2 Irrespective of the place of delivery, the place of performance or place of payment under the contract, the contract shall be deemed to have been made at the place from which the contract has been issued.
29.3 The court of the station of the depot placing the orders shall alone have the jurisdiction to decide any dispute arising out of or in respect of the contract.
30. Resolution of Disputes
30.1 The purchaser and the supplier, shall make every effort to resolve amicably by direct informal negotiation any disagreement or dispute arising between them under or In connection with the contract
30.2 If, after thirty (30) days from the commencement of such informal negotiations, the purchaser and the supplier have been unable, to resolve amicably a contract dispute, either party may require, that the dispute be referred for resolution, to the formal mechanism specified in clause 30.3.below. 30.3 The dispute resolution mechanism to be applied pursuant to clause 30.2 shall be as follows:
a) In event of any dispute or difference between the parties hereto, such disputes or differences shall be resolved amicably by mutual consultation. If such resolution is not possible, then the unresolved dispute or difference shall be referred to arbitration of the sole arbitrator to be appointed by Ministry of Health on the recommendation of the Secretary, Department of Legal Affairs (“Law Secretary”), Government of India. The provisions of Arbitration and Conciliation Act, 1996 (No. 26 of 1996) shall be applicable to the arbitration under this clause. The venue of such arbitration shall be at Delhi or any other place, as may be decided by the arbitrator. The language of arbitration proceedings shall be English. The arbitrator shall make a reasoned award (the “Award”), which shall be final and binding on the parties”. The expenses of the arbitration proceedings shall be shared equally by the parties to the agreement. However, Expenses incurred by each party in connection with the preparation, presentation shall be borne by the party itself. b) Pending the submission of and / or decision on a dispute, difference or claim or until the arbitral award is published, the Parties shall continue to perform all of their obligations under this Agreement without prejudice to a final adjustment in accordance with such award.
31.4 The venue of arbitration shall-be New Delhi or the stations of respective depots placing orders
No:GMSD/KOL/Generic-01 24 ANNEXURE-A LETTER OF UNDERTAKING (To be given on Company Letter Head) To The Sr. Chief Medical Officer (SAG) & I/C Govt. Medical Store Depot, 9, Clyde Row, Hastings, Kolkata-700022
Sub: Letter of Undertaking and Acceptance of Terms & Conditions of Tender. Tender Reference No: ------Madam/Sir,
(1) I/We hereby offer to supply the stores detailed in the Tender Document, or such portion thereof as you may specify in the order, at the price given in the Price Bid (Annexure-L) and agree to hold this offer open till 120 days from the date of the Tender opened or extended date of opening. (2) I/We have read and understood the Tender Document and instruction to Bidders mentioned in therein which form part of the contract /agreement and I / we shall abide hereby by the terms / conditions / clauses contained therein and examine the specifications quoted in the Tender hereto and am/are fully aware of the nature of the stores required and my/our offer is to supply stores strictly in accordance with the requirement.
(3) I/We further convey our unconditional acceptance to all your standard terms and conditions specified in the Tender Document (s)/ Corrigendum(s) and the instructions to Bidders, in to to.
(4) In case any provisions of this tender are found violated , then your department/ organization shall without prejudice to any other right or remedy be at liberty to reject this tender/bid including the forfeiture of the full said earnest money deposit absolutely.
(5) All the Tender documents are duly filled in and signed by me/us with stamp / seal.
Yours faithfully, (Signature of Bidder) Name in Block Letters ______Capacity in which Tender has been signed with rubber seal ______Address in Full ______Date Place
Signature of Witness.
Address ______
Date Place
Authorized signatory should attach in original letter of authority on the letter head of the firm duly signed by a Proprietor / partners / companies through memorandum of association / board meeting
No:GMSD/KOL/Generic-01 25 Annexure-B
TenderInviting Authority: NameofWork: ContractNo. BidderName:
TECHNICALBID Sl. Item VMS Item Quan Spe Shel Packi Man Self Mark Page Page Page Page Page No Descripti No. Grou tity cific f ng ufact Mfg. eted No No No No No on ( p atio Life ured / by atwhi atwhi atwhic atwh atwhi by loan Nomencl n of Lice ch chGM hManu ich ch ature+St offe item nce Manu P facturi Prod Label red rength offer /3rdp factur or ng & uctio sof + Dosage ed arty ing WHO Market n prima Form+ (in Licen GMP ing Certi ry Specifica Mon se or experi ficat and tion + ths) subm CoPP ence e seco Pack itted Certifi certific And ndary Size,if cate ate Actu packi relevant ) submit submit al ng of ted ted Prod the uctio prod n ucts Detai subm ls itted sub mitte d
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1 2 3 4 5 1. Note-Specification of the drugs should be IP/ NFI if the product is officially in IP/NFI. Where Item is not included in the IP/ NFI ,The Specification Should be as per Drug Manufacturing License / permitted by the Drug Control Authorities 2. Abbreviations for indicating Specification IP Indian Pharmacopeia NFI National Formulary Of India BP British Pharmacopeia USP US Pharmacopeia CPT Confirming to Performance Test as per Specification of the Drug as per Drug Manufacturing License/permitted by the Drug Control Authorities
No:GMSD/KOL/Generic-01 26 ANNEXURE-C
MANUFACTURING / IMPORTING& MARKETING CERTIFICATE
This is to certify that M/s______are holding valid manufacturing/import Licence No. .______date______of the State and they are manufacturing/importing the following products since the last three years (36 months).
It is further certified that the following products are also being marketed for the last three years (36months).
S. No. Name of the product Pharmacopoeia Specification Strength
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Signature and seal of Manufacturer/Bidder
or
Chartered Accountant
Dated:
Note: -
1. Firm should have three years (36 months) experience of marketing and manufacturing/import as on date of opening of the Tender. Bidders holding loan licenses are also acceptable. No:GMSD/KOL/Generic-01 27 ANNEXURE-D
PRODUCTION / IMPORT CERTIFICATE
Indicate details of production/import of the items quoted, for the last three years (36 months) duly certified by the concerned Manufacturer/Bidder or Chartered Accountant.
Sl. No. of the items as Name & specification of Date of issue of Mfg. License for the Date of marketing the in Tender enquiry the item product 1st batch
1. 2. 3. 4
ACTUAL PRODUCTION / IMPORT DETAILS
1ST year 2nd year 3rd year Remarks
Batch No. Batch size Batch No. Batch size Batch No. Batch size
1. 2. 3. 4. 5. 6. 7.
Signature of the Manufacturer/Bidder or Chartered Accountant
Signature along with address & seal of
Manufacturer/Bidder or Chartered Accountant
Note: Firm will have to produce documentary evidence including excise duty paid document in respect of production as and when asked for.
No:GMSD/KOL/Generic-01 28 ANNEXURE-E
Bid Form
(Proforma To Be Filled In By The Bidder.)
(I) GENERAL INFORMATION (a) Name of the firm. (b) Address & Telephone No. (c) Whether the firm is Indian / Multi-national. (d) Whether small / medium / large-scale company. (e) Person responsible for conduct of business. (f) Particulars of Licenses held under Drugs & Cosmetics Act & the details. (If the license is under renewal. Certificate from the Drug Controller that the License is under renewal and deemed to be in force should be enclosed. (g) Procurement agency with which registered and the agencies to whom drugs quoted supplied during last one year. (h) (i) Has the firm even been convicted, if yes give details. (ii) Any case pending in Court with details. (i) Have the firm ever been black listed / debarred by any procurement agency. If yes, details thereof. (j) Has the firm ever been debarred / black listed for supply of drug / drugs by M.S.O. If yes, give details.
(II) FINANCIAL (a) Annual turnover for formulations during the last three years. (Year wise). (b) Name and address of the bankers to the firm and the facilities available for the bank. (c) Income tax No. / Central sales tax No. / State sales tax No./
DECLARATION
______proprietor / partner / director of M/s ______hereby declare that the information given in this form is true and correct to the best of my knowledge and belief.
(Signature of the Bidder) Name in block letters Capacity in which the Tender has been signed with stamp/seal Address in full
E-mail Address
Fax No. Telephone No. Date
No:GMSD/KOL/Generic-01 29 Annexure-F To, (Name of purchaser)
Sub: Certificate regarding de-registration/ debarred / blacklisted / banning / suspended for business etc.
Ref Tender Reference No……………………… due on…………………………
We certify that we have not been de-registered or debarred or blacklisted or banned / suspended for business for any product or constituent of the product we have quoted, by Medical Stores Organisation (MSO) / GMSD, Director General of Health Services, Ministry of Health & Family Welfare, GOI, New Delhi / Drugs Controller, till the due date of submission of BID as specified in the subject BID. If we, at a later date, are found guilty of suppressing facts in this regard, such act on our part shall be considered a fraudulent practice in accordance with the Instructions to Bidders and the Purchaser shall be entitled to reject our BID and forfeit the BID Security for the product quoted, submitted by us against this Tender.
We have also noted that after submission of BID and before award contract, if we are deregistered or debarred or blacklisted by Medical Stores Organisation (MSO) of Directorate General of Health Services, Ministry of Health & Family Welfare, GOI / Drug Controller, our BID will be considered as Non-responsive.
Date ______Signature ______
Place ______Print Name ______
Designation ______
Common Seal ______
No:GMSD/KOL/Generic-01 30
Annexure-G1 Check list of Documents to be submitted in Volume-I of Technical Bid
SlNO Documents to be submitted in Cover “A” At PageNo 1 Fees for Tender Form 2 EMD or Copy of valid NSIC Registration Certificate if applicable Check list of Documents to be submitted in Volume-I of Technical Bid
SlNO Documents to be submitted in Cover “B” At PageNo 1 Forwarding letter of the firm. 2 Self-attested copy of notarized power of attorney. 3 Letter of Undertaking as per Annexure- “A ” 4 Audited financial statement (Balance-Sheet and profit & Loss Account Statement) in respect of annual turnover for formulations. 5 Declaration duly certified by the Chartered Accountant(CA) that the manufacturer has not less than 50% of Annual Turnover from trade i.e. outside institution/Govt. supplies.
6 Name and Address of the Banker/ Bankers 7 Copies of PAN Card, Registration Certificate with VAT and latest VAT Return. 8 Duly filled Questionnaire as per Annexure-H 9 Non-conviction certificate for three continuous years from the Licensing Authority/ Drug Controller of the State 10 General & Financial information and declaration duly filled as per Annexure-E 11 Certificate regarding de-registration/debarred/ blacklisted / banning/ suspended for business etc. as per Annexure-F 12 Copy of Manufacture Agency Agreement as per Annexure-Jif applicable
13 UndertakingthatthebidderismarketingquoteddrugsatleastinallcitieswhereCGHS/GMS Darelocated in case of group A drugs. 14 Certificate signed by Head of their quality Assurance department that manufacturing firm have their own R&D facilities where they are conducting at least routine testing, stability profile, quality assurance etc. of drug being manufactured in case of Group A drugs. 15 Certificate that bidder have manufactured and marketed not less than the quantity indicated in the bid for the quoted drug during last one year in case estimated withdrawal of drug is indicated in Annexure-K
(Signatureof the Bidder)
Name in block letters Capacity in which the Tender has been signed with stamp/seal
No:GMSD/KOL/Generic-01 31 Annexure-G2
Check list of Documents to be submitted in Volume-II of Technical Bid
Sl Documents to be submitted At Page No No 1 Copy of Valid Drug Manufacturing License/Import License with the list of products approved. 2 Copy of valid GMP or WHO GMP or CoPP (Certificate of Pharmaceutical Product) Certificate in respect of the formulations/drugs quoted in the Tender whichever is applicable. 3 Copy of Certificate of original manufacturer of product from the State Drug Controller) if any. 4 Copy of Certificate of sole manufacturer of product from State Drugs Controller if any.
(Signature of the Bidder)
Name in block letters Capacity in which the Tender has been signed with stamp/seal
No:GMSD/KOL/Generic-01 32 Annexure-G3
Check list of Documents to be submitted in Volume-III of Technical Bid
Sl Documents to be submitted At No PageNo 1 Three years(36 months) manufacturing &marketing experience certificate duly signed by the Manufacturer / Bidder or Chartered Accountant in prescribed format i.e. Annexure-“C ”(not more than one year old on the date of opening of the Tender)and Certificate of approval of Drug Controller General of India for new drugs If any. 2 Production/ Import certificate for the last three years (36 months) in respect of drugs quoted as per Annexure “D”.
(Signature of the Bidder)
Name in block letters Capacity in which the Tender has been signed with stamp/seal
No:GMSD/KOL/Generic-01 33 Annexure-G4
Check list of Documents to be submitted in Volume-IV of Technical Bid
Sl Documents to be submitted At No PageNo 1 Copies of the Labels of primary and secondary packing of the products for which the offer is being made should also be submitted.
(Signature of the Bidder)
Name in block letters Capacity in which the Tender has been signed with stamp/seal
No:GMSD/KOL/Generic-01 34 Annexure-H
Sl .NO Questions Reply 1 What is your Assessed/Installed capacity? Have you enclosed documentary evidence in support there of 2 (i)Are you registered as small Scale unit with the NSIC. If so, indicate your current Registration number and date and period up to which the registration is valid. (ii)In case you are registered with NSIC for the item quoted, confirm whether you have attached a photocopy of the registration certificate Indicating the items for which you are registered. 3 Have you furnished attested copy of your latest and valid Drug Manufacturing License issued by State Drug Controller indicating each of the item for which Tender is submitted. 4 Have you furnished attested copy of your latest and valid G.M.P. or WHOGMP or COPP Certificate for the Items quoted in the Tender submitted. 5 Have you furnished attested copy of PAN Card ,Registration Certificate with VAT and latest VAT Return 6 Have you furnished attested copy of last three years statement of accounts duly audited and certified by CA/Auditor in support of your annual turnover of Rs. 50 Crore or Rs100 Crore and above 7 Have you furnished a notarised copy of the power of attorney in favour of the persona(s)signing the BID to bind the manufacturer /Bidder to the contract. 8 Does the product fall under the previews of Essential Commodities Act 1955 and Drugs Price Control Order 2013 and the price quoted do not exceed notified price. 9 Have you furnished your performance statement of the orders for Tendered drugs 10. Have you furnished a declaration duly certified by the Chartered Accountant (CA)that the manufacturer has not less than 50% of Annual Turnover from trade i.e. out side institution/Govt. supplies.
(Signature of the Bidder)
Name in Block Letters…………………..Seal Date
No:GMSD/KOL/Generic-01 35 Annexure-I Guidelines for action to be taken against the Manufacturing unit and the contract holding firms in the event of failure of drug in laboratory test.
In the event of drugs supplied found substandard in laboratory test, the following deregistration / debarment action will be taken against the manufacturing unit and contract holding firms debarment action will be taken against the manufacturing unit and contract holding firms
(i) For Category 'B' defects, the manufacturer and contractor will be debarred for supply to MSO of that particular product declared not of standard quality for a period of three (3) years from the date of failure. (ii) In regard to category 'A' defects, the supplier should be debarred for the supply of that product for three years from the date of failure and for repeated failure of category „A‟ defect within one year from previous date of failure, the supplier shall be debarred from supply of all the products for five (5)years.
List of Category 'A' defects and Category 'B' Defects are as follows
CATEGORY 'B' DEFECTS
TABLETS
i) Presence of spot/discoloration ii) Lump formations in few containers due to moisture. iii) Failing in uniformity of weight. iv) Picking. v) Chipping. vi) Capping. vii) Rough surfaces. viii) Brittle Tablets. ix) Non uniformity in diameter. x) Uneven coating. xi) Non declaration of colour used on the label. xii) Failing in limit test (e.g. free salicylic acid). xiii) Assay 70% and above of the label claim for thermo labile products and 5% within permitted limits for thermo stable products. xiv) Failing in particle size (Griseofulvin tablets). xv) Net content. CAPSULES
i) Presence of spots/discoloration. ii) Lump formation in container due to moisture. iii) Failing in uniformity of weight. iv) Cake/lump formation of content of capsule. v) Failing in limit tests (e.g. Analgin and Nifedipine capsules). vi) Assay-70% and above of the label claim for thermo labile products and 5% within permitted limits for thermo stable products. vii) Net content.
LIQUID ORALS (syrups /elixirs /solutions/suspensions/ emulsions / mixtures etc.)
i) Presence of foreign matter. ii) Change of colour.
No:GMSD/KOL/Generic-01 36 iii) Presence of suspended matter. iv) Cracking of emulsion. v) Sedimentation. vi) Dispersible cake/lump formation. vii) Net content. viii) Non declaration of colour on label. ix) Assay-70% and above of the label claim for thermo labile products and 5% within permitted limits for thermo stable products. x) Minor variation in pH.
EXTERNAL PREPERATIONS (ointment/solutions/cream/liniment/lotions/emulsions/like preparations). i) Separation of phases. ii) Foreign matter. iii) Consistency/ homogeneity. iv) Extradition of content from tube (outside the nozzle/cap). v) Limit test (e.g. kinetic viscosity). vi) Weight/ml. vii) Assay-70% and above of the label claim for thermo labile products and 5% within permitted limits for thermo stable products.
OPTHALMIC PREPARATIONS (eye ointment/drops/solutions etc.)
i) Presence of particulate matter. ii) Odour. iii) Clarity. iv) Extradition of content from tube/container v) Consistency. vi) Particles. vii) Assay-70% and above of the label claim for thermo labile products and 5% within permitted limits for thermo stable products. viii) Minor variation in pH.
POWDERS (oral use)
i) Assay-70% & above of the label claim for thermo labile products and 5% within permitted limits for thermo stable products. ii) Formation of mass/lump/cake) due to moisture.
INJECTABLES, INCLUDING TRANSFUSION FLUIDS.
i) Presence of particulate matter/glass pieces/precipitation. ii) Change of colour/description. iii) Extractable volume. iv) Uniformity of weight (for dry powders). v) Particle size. vi) Assay-70% and above of the label claim for thermo labile products and 5% within permitted limits for thermo stable products.
No:GMSD/KOL/Generic-01 37 vii) Isolated case of fungus growth.
COSMETICS i) Net content. ii) Not conforming to any other standard as mentioned in IS except for heavy metal test.
BULK DRUGS i) Description. ii) Solubility. i) Any other test specified in monograph not mentioned in Category A.
AEROSOLS / INHALATIONS. i) Assay-70% and above of the label claim for thermo labile products and 5% within permitted limits for thermo stable products. ii) Number of deliveries per container /water content/deposition of omitted dose (limit). iii) Particulate matter. iv) Pressure testing. v) Delivery rate. vi) Tests such as total acids. MECHANICAL CONTRACEPTIVES (Condoms). i) Description. ii) Air inflation test. iii) Dimensions iv) Colour fastness.
INTRAUTERIAL CONTRACEPTIVES DEVICES. i) Description. ii) Full test. iii) Flexibility
CATEGORY „A‟ DEFECTS.
TABLETS. i) Assay- below 70% for thermo labile products and below 5% of the permitted limits for thermo stable products. ii) Disintegration (except for marginal variation to be viewed on case to case basis). iii) Dissolution (except for marginal variation to be viewed on case to case basis). iv) Contamination with foreign matters. v) Most of the tablets observed in powder form inside the strip pouches. vi) Content uniformity. vii) Addition of permitted colour when not recommended in Pharmacopoeia.
CAPSULES.
i) Assay- below 70% for thermo labile products and below 5% of the permitted limits for thermo stable products.
No:GMSD/KOL/Generic-01 38 ii) Disintegration (except for marginal variation to be viewed on case to case basis). iii) Dissolution (except for marginal variation to be viewed on case to case basis). iv) Content uniformity. LIQUID ORALS i) Assay- below 70% for thermo labile products and below 5% of the permitted limits for thermo stable products. ii) Presence of foreign matter such as fly/insect. iii) Fungus growth. iv) Non dispersible cake/lump formation. v) Addition of non-permissible colors. EXTERNAL PREPARATIONS. i) Assay- below 70% for thermo labile products and below 5% of the permitted limits for thermo stable products. ii) Phenol coefficient (RWC) less than label claim
Grade I : less than 16
Grade II : less than 8
Grade III: less than 4
For other soluble disinfectants below 80% of the required limit. iii) Fungal growth.
OPTHALMIC PREPARATION i) Assay- below 70% for thermo labile products and below 5% of the permitted limits for thermo stable products ii) Foreign matter. iii) Metal particles. iv) Fungal growth. v) Fails in sterility.
POWDERS (Oral use). i) Assay- below 70% for thermo labile products and below 5% of the permitted limits for thermo stable products. ii) Fungal growth.
POWDERS (External use) i) Assay-below 70% for thermo labile products and below 5% of the permitted limits for thermo stable products. ii) Fungal growth.
INJECTIONS INCLUDING TRANSFUSION FLUIDS. i) Sterility. ii) Pyrogen test. iii) Toxicity. iv) Assay- below 70% for thermo labile products and below 5% of the permitted limits for thermo stable products. No:GMSD/KOL/Generic-01 39 v) Fails in any other biological test. vi) Fungal growth in different samples from different sources of same batches.
STERILE DISPOSABLE PERFUSION SETS. i) Sterility. ii) Pyrogen test. iii) Toxicity.
STERILE DISPOSABLE HYPODERMIC SYRINGES. i) Sterility. ii) Pyrogen test. iii) Toxicity.
STERILE DISPOSABLE HYPODERMIC NEEDLES. i) Sterility. ii) Pyrogen test. iii) Toxicity.
BULK DRUGS i) Assay-less than permitted limits. ii) Heavy metal test/arsenic test. iv) Sterility. Toxicity. v) Microbial limit test.
AEROSOLS/INHALATIONS i) Assay-below 70% for thermo labile products and below 5% of the permitted limits for thermo stable products. ii) Leak test.
SERA/VACCINE i) Toxicity. ii) Sterility. iii) Potency.
SUTURES/CATGUTS i) Sterility. ii) Tensile strength.
MECHANICAL CONTRACEPTIVES i) Water leakage test. ii) Tensile properties .
INTRAUTERINE CONTRACEPTIVE DEVICES
No:GMSD/KOL/Generic-01 40
i) Memory test. ii) Ash content. iii) Sterility. iv) Implantation test.
COSMETICS i) Use of non-permitted colours/dyes ii) Presence of heavy metal.
No:GMSD/KOL/Generic-01 41 Annexure-J
MANUFACTURERES AGENCY AGREEMENT
To
The Sr. Chief Medical Officer (SAG) & I/C Govt. Medical Store Depot, 9, Clyde Row, Hastings, Kolkata-700022
Dear Sir,
Tender No:------
1. We------who are established and reputable manufacturer of -----
------having factories at------and------hereby authorize M/s------
------(Name & Address) to bid, negotiate and conclude the contract with
you against Tender no.------for the above goods manufactured by us.
2. No company of firm or individual other than M/s------are authorized to bid negotiate and conclude the contract in regard to this business against this
specific tender as also for a business in the entire territory of India.
3. This agreement is valid from------to------(This period will be the date of
opening of tender contract till valid one year after the shelf life of drugs/consumables or the period of Rate-Contract whichever is more).
4. The ex-factory cost of the equipment or stores being quoted will be provided by us whenever called for. We also undertake that we will not quote a a price higher than supplied to any institute in last 6 months. In case our submission is found wrong, we undertake to be liable for punitive action in the form of recovery of excess amount/ withholding of payment/ any other action as deemed appropriate by department.
5. An Agency commission of------% is included in the gross ex-works price is applicable of
M/s------
6. We hereby extend our full guarantee and warrantee as per relevant conditions of contract for the goods offered for supply against this invitation for bid by the above firm. In the event of failure by authorized agent or distributor in honoring the contract, we undertake to provide remedial action at the earliest without any additional charges. 7. Our other responsibilities include.
No:GMSD/KOL/Generic-01 42 i. Provision of requisite inspection and testing facilities at our works in respect of supply order placed on our agent.
ii. ------
{Here specify in detail manufacturers responsibilities]
The services to be rendered by the agent, M/s------are as under:-
i. ------
ii. ------
{Here specify the services to be rendered by the agent}
8. We certify that neither we, nor our agent is blacklisted/ debarred by any Govt. agency.
9. We jointly agree to abide by the following clauses in the contract: a) Penalty for use of undue influence. b) Access to books of accounts. 10. We undertake that CST/ VAT registration number, Permanent Account Number (PAN), last three years Bank Statement of Accounts, Banker details of our authorized agent/ distributor will be provided as and when demanded by the department.
Yours faithfully,
(Name, Signature & Stamp) (Name, Signature & Stamp)
(Name of Authorized Agent/ Distributor) (Name of Manufacturer)
Date: Date:
NOTE:
THIS LETTER OF AUTHORIZATION SHOULD BE ON THE ORIGINAL LETTER HEAD OF THE MANUFACTURING CONCERN AND SHOULD BE INK SIGNED BY BOTH THE ORIGINAL MANUFACTURERE & THE AUTHORIZED DISTR / AGENT, BY A PERSON WHO IS COMPETENT AND HAVING THE POWER OF ATTORNEY TO BID THE MANUFCTURERE, A COPY OF NOTARIZED POWER OF ATTORNEY SHOULD ALSO BE FURNISHED, NAME, SIGNATURE AND OFFICAL STAMP OF MANUFACTURER AND AGENT TO BE APPENDED.
No:GMSD/KOL/Generic-01 43 Annexure-K Schedules of Requirements Listofdrugsforwhichbidsareinvited,alongwith specificationandEMDRequirement:
SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 1 G05003 Carbamazepine Syrup 100 mg / 5 ml A 1 50 ml Bottle 2 G05008 Phenytoin Tablet I.P 50mg A 1 3 G05010 Phenytoin Oral Suspension I.P A 1 125mg/5ml 100 ml Bottle 4 G05014 Sodium Valproate Oral Solution I.P A 1 200 mg / 5 ml 100 ml Bottle 5 G05021 Oxcarbazepine Tablet I.P 250mg A 1 6 G05024 Zonisamide Tablet 100mg. A 1 7 G06037 Azithromycin Capsule I.P 100 mg A 1 8 G06038 Azithromycin Tablet I.P 250mg A 1 9 G06039 Azithromycin Tablet I.P 500mg A 1 10 G06040 Azithromycin Suspension 100 mg / 5 A 1 ml 15ml Bottle 11 G06045 Clarithromycin Tablet I.P 500mg A 1 12 G06073 Clofazimine Capsule I.P 50mg A 1 13 G06074 Clofazimine Capsule I.P 100mg A 1 14 G06113 Aciclovir Tablet I.P 200 mg A 1 15 G06114 Aciclovir Tablet I.P 400mg A 1 16 G06117 Aciclovir Suspension 400 mg / 5 ml A 1 60 ml Bottle 17 G06166 Levofloxacin Tablet 500mg A 1 18 G06171 Cefaclor Capsule I.P 500mg A 1 19 G06172 Cefpodoxime Tablet I.P 100mg A 1 20 G06174 Cefadroxine Tablet 500mg A 1 21 G06179 Clarithromycin Tablet I.P 250mg A 1 22 G06194 Amoxycillin and Cloxacillin A 1 Dispersible Tablet 125mg + 125mg 23 G06206 Cefixime Tablet I.P 100mg A 1 24 G06207 Cefixime Oral Suspension 50mg/5ml A 1 30ml Bottle 25 G06210 Clindamycin Capsule I.P 150mg A 1 26 G06211 Clindamycin Capsule I.P 300mg A 1 27 G06245 Amoxycillin and Potassium A 1 Clavulanate Dry Syrup 125MG+ 31.25MG 30ml Bottle as- EACH 5 ML OF RECONSTITUTED SUSPENSION CONTAINS : AMOXICILLIN TRIHYDRATE IP EQUIVALENT TO AMOXICILLIN 125 MG , CLAVULANATE POTASSIUM DILUTED IP EQUIVALENT TO CLAVULANIC ACID 3 28 G06247 Amoxycillin and Potassium A 1 Clavulanate Dispersible Tablet 125MG+ 31.25MG as- EACH
No:GMSD/KOL/Generic-01 44 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal UNCOATED DISPERSIBLE TABLET CONTAINS:AMOXYCILLIN TRIHYDRATE IP EQ. TO AMOXYCILLIN 125MG,DILUTED POTASSIUM CLAVULANATE BP EQ. TO CLAVULANIC ACID 31.25MG 29 G06251 Ampicillin and Sulbactam Tablet A 1 220MG+ 147MG as- EACH FILM COATED TAB CONTAINS SULTAMICILLIN (AS TOSYLATE) 375MG (EQ. TO SULBACTAM 147MG, AMPICILLIN 220MG) COLOUR TITANIUM DIOXIDE 30 G07003 Sumatriptan Tablet 25mg A 1 31 G07004 Sumatriptan Tablet 50mg A 1 32 G07005 Rizatriptan Tablet 5mg A 1 33 G07007 Flunarizine Tablet 5mg A 1 34 G08002 Cyclosporine Capsule 10 mg A 1 35 G08003 Cyclosporine Capsule 25 mg, A 1 36 G08004 Cyclosporine Capsule 50mg A 1 37 G08005 Cyclosporine Capsule 100mg A 1 38 G08011 Busulphan Tablet I.P 2 mg A 1 39 G08014 Cyclophosphamide Tablet I.P 50mg A 1 40 G08020 Danazol Capsule I.P 50mg A 1 41 G08021 Danazol Capsule I.P 100mg A 1 42 G08024 Etoposide Capsule I.P 100mg A 1 43 G08026 Flutamide Capsule I.P 250 mg A 1 44 G08032 Melphalan Tablet I.P 2 mg A 1 45 G08033 Melphalan Tablet I.P 5mg A 1 46 G08034 Mercaptopurine Tablet I.P 50 mg A 1 47 G08040 Procarbazine Capsule 50 mg A 1 48 G08045 Raloxifene Tablet 60 mg A 1 49 G08046 Tamoxifen Tablet I.P 10 mg A 1 50 G08050 Ondansetron Tablet I.P 8mg A 1 51 G08052 Ondansetron Oral Solution I.P A 1 2mg/5ml 30 ml Bottle 52 G08054 Imatinib Capsule I.P 100 mg A 1 53 G08055 Hydroxyurea Capsule 500mg A 1 54 G08065 Anastrazole Tablet I.P 1mg A 1 55 G08072 Imatinib Capsule I.P 400 mg A 1 56 G08075 Methotrexate Tablet I.P 7.5mg A 1 57 G08078 Thalidomide Tablet 50mg A 1 58 G08079 Thalidomide Tablet 100mg A 1 59 G12002 Glyceryl Trinitrate Tablet I.P 0.5 mg A 1 60 G12005 Isosorbide Dinitrate Tablet I.P 20 mg A 1 61 G12025 Mexiletine Capsule I.P 50mg A 1 62 G12026 Mexiletine Capsule I.P 150mg A 1 63 G12028 Procainamide Tablet I.P 250 mg A 1 64 G12030 Quinidine Tablet I.P 100mg A 1 65 G12032 Verapamil Tablet I.P 80mg A 1
No:GMSD/KOL/Generic-01 45 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 66 G12039 Chlorthalidone Tablet I.P 25 mg A 1 67 G12040 Chlorthalidone Tablet I.P 50mg A 1 68 G12042 Clonidine Tablet I.P 150mcg A 1 69 G12050 Nifedipine Capsule I.P 5mg A 1 70 G12051 Nifedipine Capsule I.P 10mg A 1 71 G12054 Nifedipine Sustained Release Tablet A 1 I.P 10mg 72 G12055 Nifedipine Sustained Release Tablet A 1 I.P 20mg 73 G12058 Terazosin Tablet 2mg A 1 74 G12059 Terazosin Tablet 5mg A 1 75 G12062 Digoxin Paediatric Solution I.P 50mcg A 1 / ml Bottle 76 G12066 Soluble Aspirin Tablet I.P 100mg as- A 1 EACH UNCOATED EFFERVESCENT TABLET CONTAINS ACETYL SALICYLIC ACID IP 100MG EFFERVESCENT BASE:QS 77 G12072 Atenolol and Chlorothiazide Tablet A 1 50mg + 12.5mg 78 G12073 Enalapril and Amlodipine Tablet 5mg A 1 + 5mg as- EACH CAPSULE CONTAINS: ENALAPRIL MALEATE IP 5MG , AMLODIPINE BESYLATE BP EQ.TO AMLODIPINE 5MG 79 G12083 Labetalol Tablet 10mg A 1 80 G12085 Soluble Aspirin Tablet I.P 350 mg as- A 1 EACH UNCOATED EFFERVESCENT TABLET CONTAINS ACETYLSALICYLIC ACID IP 350MG, EFFERVESCENT BASE:QS 81 G12100 Labetalol Tablet I.P 100mg A 1 82 G12101 Labetalol Tablet I.P 200mg A 1 83 G12134 Clonidine and Hydrochlorothiazide A 1 Tablet 100MCG+ 50MG as- EACH UNCOATED TABLET CONTAINS: CLONIDINE HYDROCHLORIDE IP 100MCG, HYDROCHLOROTHIAZIDE IP 20MG EXCIPIENT Q.S. COLOUR QUINOLINE YELLOW W.S 84 G12137 Aspirin and Clopidogrel Enteric A 1 Coated Tablet 162.5MG+ 75MG as- EACH FILM COATED TAB. CONTAINS: CLOPIDOGREL BISULFATE EQ. TO CLOPIDOGREL 75MG, ASPIRIN 162.50MG (AS ENTERIC COATED GRANULES) EXCIPIENTS Q.S. 85 G12156 Aspirin and Glycine Tablet 150MG+ A 1 75MG as- ASPIRIN + GLYCINE 150MG+75MG 86 G12157 Aspirin and Glycine Tablet 75MG+ A 1
No:GMSD/KOL/Generic-01 46 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 37.5MG as- ASPIRIN + GLYCINE 75MG+37.5MG 87 G12158 Atenolol and Indapamide Tablet A 1 50MG+ 2.5MG as- EACH UNCOATED TABLETS CONTAINS ATENOLOL IP 50MG INDAPAMIDE USP 2.5MG 88 G12163 Propranolol Capsule 40MG as- A 1 EACH CAPSULE CONTAINS PROPRANOLOL HYDROCHLORIDE IP 40MG (AS EXTENDED RELEASE PELLETS) 89 G12181 Indapamide Sustained Release Tablet A 1 1.5MG as- EACH SUSTAINED RELEASEFILM COATED TABLET CONTAINS INDAPAMIDE USP 1.5MG 90 G12186 Metoprolol Extended Release Tablet A 1 50MG as- EACH EXTENDED RELEASED COATED BILAYER TABLET CONTAINS METOPROLOL SUCCINATE USP 47.50MG EQ. TO METOPROLOL TARTRATE 50MG 91 G12189 Metoprolol Extended Release Tablet A 1 25MG as- EACH EXTENDED RELEASE FILM COATED TABLETS CONTAINS METOPROLOL SUCCINATE USP 23.75MG EQ. TO METOPROLOL TARTRATE 25MG 92 G16003 Hydrochlorothiazide Tablet I.P 25 mg A 1 93 G16008 Frusemide and Amiloride Tablet 20 A 1 mg + 5mg 94 G16009 Hydrochlorothiazide and Amiloride A 1 Tablet 50mg + 5mg as- EACH UNCOATED TABLET CONTAINS:AMILORIDE HCL IP 5MG (AS ANHYDROUS) , ,HYDROCHLORTHIAZIDE IP 50MG 95 G18006 Testosterone undecanoate Capsule A 1 40 mg 96 G18008 Ethinyl oestradiol and Levonorgestrel A 1 Tablet 0.03 mg +0.15 mg 97 G18009 Ethinyl oestradiol and Norethisterone A 1 Tablet 0.035 mg +1mg 98 G18014 Ethinyl oestradiol Tablet I.P 0.01mg A 1 99 G18015 Ethinyl oestradiol Tablet I.P 0.05mg A 1 100 G18016 Glibenclamide Tablet I.P 2.5 mg A 1 101 G18020 Metformin Tablet I.P 500mg A 1 102 G18023 Clomifene Tablet I.P 50mg A 1 103 G18024 Clomifene Tablet I.P 100mg A 1 104 G18025 Medroxyprogesterone Acetate Tablet A 1 5mg 105 G18026 Medroxyprogesterone Acetate Tablet A 1
No:GMSD/KOL/Generic-01 47 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 10 mg 106 G18031 Aqueous Iodine Oral Solution 8 mg / A 1 5 ml 100 ml Bottle 107 G18032 Glimepiride and Metformin Tablet A 1 1mg + 500mg 108 G18048 Equine Conjugated Estriol Tablet A 1 0.625mg 109 G18049 Estradiol Gel Single Use Patch 0.10% A 1 Sachet 110 G18058 Estradiol Valerate Tablet 1mg A 1 111 G18059 Estriol Cream Cream 0.1%W/W 15G A 1 Tube 112 G18060 Ethinyl oestradiol and Drospirenone A 1 Tablet 113 G18065 Levothyroxine Tablet 100mcg A 1 114 G18078 Glipizide and Metformin Tablet A 1 2.5MG+ 250MG as- EACH UNCOATED TABLET CONTAINS: GLIPIZIDE B.P. 2.5MG, METFORMIN HYDROCHLORIDE I. P. 250MG 115 G18081 Glimepiride and Pioglitazone Tablet A 1 2mg+ 15mg as- EACH UNCOATED TABLET CONTAINS: PIOGLITAZONE HYDROCHLORIDE EQ TO PIOGLITAZONE 15MG, GLIMEPIRIDE USP 2MG 116 G18086 Metformin Sustained Release Tablet A 1 500MG as- EACH UNCOATED SUSTAINED RELEASE TABLET CONTAINS METFORMIN HCL IP 500MG 117 G18087 Gliclazide Modified Release Tablet A 1 30MG as- EACH UNCOATED SCORED MODIFIED RELEASE TABLET CONTAINS GLICLAZIDE BP 30MG 118 G18088 Gliclazide Extended Release Tablet A 1 60MG as- EACH UNCOATED SCORED EXTENDED RELEASE TABLET CONTANS GLICLAZIDE BP 60MG 119 G01002 Halothane 250ml Bottle B 1 120 G01003 Isoflurane Inhalation 100ml Bottle B 1 121 G01006 Nitrous Oxide Inhalation 100 ml B 1 Bottle 122 G01007 Oxygen Inhalation B 1 123 G01013 Ethyl Chloride Spray 1% Container B 1 124 G01014 Lignocaine Gel I.P 2% 30 gm Tube B 1 125 G01026 Benzocaine Gel 20% 15 gm Tube B 1 126 G01027 Desflurane Inhalation 250 ml 250ml B 1 Bottle 127 G01030 Xylocaine spray 10% 50 ml Bottle B 1 128 G02005 Ibuprofen Tablet I.P 200 mg B 1
No:GMSD/KOL/Generic-01 48 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 129 G02008 Paracetamol Syrup I.P 125mg/5ml 60 B 1 ml Bottle 130 G02011 Morphine Tablet 10mg B 1 131 G02012 Pentazocine Tablet I.P 25 mg B 1 132 G02016 Colchicine Tablet I.P 0.5mg B 1 133 G02024 Diacerein Capsule I.P 50mg as- B 1 EACH CAPSULE CONTAINS DIACEREIN 50MG 134 G02025 Diclofenac Ointment 1%w/v 30 gm B 1 Tube 135 G02029 Mefenamic Acid Capsule I.P 500mg B 1 136 G02039 Diclofenac Potassium And Tizanidine B 1 Tablet 50mg+ 2mg as- EACH FILM COATED TABLET CONTAINS: TIZANIDINE HYDROCHLORIDE EQ.TO TIZANIDINE 2MG, DICLOFENAC POTASSIUM BP 50MG 137 G03003 Dexchlorpheniramine Oral Solution B 1 I.P 2mg / 5 ml 100 ml Bottle 138 G03011 Azelastine Nasal Spray 0.10% 10 ml B 1 Container 139 G03012 Fluticasone Nasal spray 100mcg B 1 100MD Container 140 G03013 Cetirizine Syrup 5mg/5ml 60 ml B 1 Bottle 141 G03014 Cyproheptadine Tablet I.P 4mg B 1 142 G03015 Fluticasone Nasal spray 50mcg 10 B 1 ml/100 md Bottle 143 G03018 Hydroxyzine Syrup 10mg/5ml 100 ml B 1 Bottle 144 G03021 Pheniramine Tablet I.P 25 mg B 1 145 G04001 Activated Charcoal Powder I.P 100 G B 1 Pkts 146 G04009 Penicillamine Tablet I.P 250 mg B 1 147 G04013 Oral Iron Chelating Agent (Calfer) B 1 Tablet 250mg 148 G04014 Activated Charcoal Tablet B 1 149 G04015 Deferasirox Tablet 100 B 1 150 G04016 Deferasirox Tablet 400 B 1 151 G04017 Deferasirox Tablet 250mg B 1 152 G04018 Deferasirox Tablet 500mg B 1 153 G05026 Carbamazepine Sustained Release B 1 Tablet 200mg as- EACH SUSTAINED RELEASE FILM COATED TABLET CONTAINS CARBAMAZEPINE IP 200MG 154 G06002 Albendazole Suspension 200 mg/ 5 B 1 ml 10 ml Bottle 155 G06003 Mebendazole Tablet I.P 100 mg B 1 156 G06004 Mebendazole Suspension 100 mg / 5 B 1 ml 30 ml Bottle No:GMSD/KOL/Generic-01 49 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 157 G06007 Pyrantel Pamoate Oral Suspension I.P B 1 250 mg / 5 ml 10 ml Bottle 158 G06008 Diethylcarbamazine Tablet I.P 50mg B 1 159 G06010 Amoxycillin Oral Suspension I.P 125 B 1 mg / 5 ml 60 ml Bottle 160 G06013 Ampicillin Capsule I.P 250mg B 1 161 G06014 Ampicillin Capsule I.P 500mg B 1 162 G06015 Ampicillin Oral Suspension I.P 125 mg B 1 / 5 ml 60 ml Bottle 163 G06031 Cloxacillin Capsule I.P 250mg B 1 164 G06032 Cloxacillin Capsule I.P 500mg B 1 165 G06034 Cloxacillin Syrup I.P 125 mg / 5 ml 40 B 1 ml Bottle 166 G06042 Cephalexin Oral Suspension I.P 125 B 1 mg / 5 ml 30ml Bottle 167 G06047 Chloramphenicol Oral Suspension I.P B 1 125 mg / 5 ml 60 ml Bottle 168 G06048 Chloramphenicol Capsule I.P 250 mg B 1 169 G06055 Trimethoprim and B 1 Sulphamethoxazole Oral Suspension I.P 40mg +200 mg / 5 ml 50 ml Bottle as- EACH 5ML CONTAINS: TRIMETHOPRIM IP 40MG, SULPHAMETHOXAZOLE IP 200MG 170 G06057 Erythromycin Estolate Suspension B 1 125 mg / 5 ml 60 ml Bottle 171 G06058 Erythromycin Estolate Tablet 250 mg B 1 172 G06059 Erythromycin Estolate Tablet 500mg B 1 173 G06063 Nalidixic Acid Tablet I.P 250 mg B 1 174 G06067 Roxithromycin Tablet I.P 50 mg B 1 175 G06069 Sulphadiazine Tablet I.P 500 mg B 1 176 G06070 Tetracycline Capsule I.P 250 mg B 1 177 G06075 Dapsone Tablet I.P 50mg B 1 178 G06076 Dapsone Tablet I.P 100mg B 1 179 G06086 Ofloxacin Syrup 50mg/5ml 60 ml B 1 Bottle 180 G06100 Clotrimazole Pessaries I.P 100mg B 1 181 G06101 Clotrimazole Pessaries I.P 200mg B 1 182 G06102 Clotrimazole Cream I.P 2% 15G Tube B 1 183 G06103 Fluconazole Tablet I.P 50mg B 1 184 G06106 Fluconazole Tablet I.P 200mg B 1 185 G06107 Flucytosine Capsule I.P 250 mg B 1 186 G06108 Griseofulvin Tablet I.P 125 mg B 1 187 G06110 Ketoconazole Tablet I.P 200 mg B 1 188 G06111 Nystatin Tablet I.P 500,000 IU B 1 189 G06112 Nystatin Pessary I.P 100,000 IU B 1 190 G06118 Didanosine Tablet I.P 250mg B 1 191 G06119 Didanosine Tablet I.P 400mg B 1 192 G06120 Lamivudine Tablet I.P 150 mg B 1 193 G06122 Lamivudine and Zidovudine Tablet I.P B 1
No:GMSD/KOL/Generic-01 50 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 150 mg + 300 mg as- LAMIVUDINE 150 MG ZIDOVUDINE 300 MG 194 G06123 Stavudine Capsule I.P 15mg B 1 195 G06124 Stavudine Capsule I.P 30mg B 1 196 G06125 Stavudine Capsule I.P 40mg B 1 197 G06126 Zidovudine Tablet I.P 100 mg B 1 198 G06127 Zidovudine Tablet I.P 300mg B 1 199 G06128 Efavirenz Capsule I.P 200mg B 1 200 G06129 Efavirenz Capsule I.P 600mg B 1 201 G06130 Nevirapine Tablet I.P 200 mg B 1 202 G06131 Nevirapine Suspension I.P 50mg / B 1 5ml 100 ml Bottle 203 G06132 Indinavir Capsule I.P 200 mg B 1 204 G06133 Indinavir Capsule I.P 400mg B 1 205 G06134 Nelfinavir Tablet I.P 250mg B 1 206 G06135 Ritonavir Capsule I.P 100 mg B 1 207 G06136 Ritonavir Syrup 400mg/5ml 100 ml B 1 Bottle 208 G06137 Saquinavir Tablet I.P 200 mg B 1 209 G06138 Diloxanide Tablet I.P 500mg B 1 210 G06144 Chloroquine Phosphate Tablet I.P B 1 approximately equivlent to 155mg base 211 G06146 Chloroquine Phosphate Suspension B 1 I.P 50 mg / 5 ml 60 ml Bottle 212 G06147 Primaquine Tablet I.P 2.5 mg B 1 213 G06148 Primaquine Tablet I.P 7.5mg B 1 214 G06149 Pyrimethamine Tablet I.P 25mg B 1 215 G06150 Quinine Tablet I.P 300mg B 1 216 G06152 Pyrimethamine and Sulfadoxine B 1 Tablet I.P 25mg+500mg as- EACH UNCOATED TABLET CONTAINS : PYRIMETHAMINE I.P. 25MG, SULPHADOXINE I.P. 500MG 217 G06154 Trimethoprim Tablet I.P 100 mg B 1 218 G06187 Famciclobir Tablet 250mg B 1 219 G06188 Dihydroxychloroquine Tablet 200mg B 1 220 G06199 Amoxycillin Dispersible Tablet I.P 125 B 1 mg 221 G06201 Artesunate Tablet 50mg B 1 222 G06213 Clotrimazole Lotion 1%w/v 15ml B 1 Bottle 223 G06214 Clotrimazole Cream I.P 1%w/w 15G B 1 Tube 224 G06215 Clotrimazole and Clindamycin B 1 Pessaries 200mg+100mg 225 G06216 Colistin Sulphate Syrup 12.5 mg /5ml B 1 30ml Bottle 226 G06217 Erythromycin stearate Suspension B 1 125mg/5ml 60ml Bottle
No:GMSD/KOL/Generic-01 51 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 227 G06218 Erythromycin stearate Tablet I.P B 1 250mg 228 G06225 Ivermectin and Albendazol Tablet B 1 229 G06226 Levamisole Tablet I.P 50mg B 1 230 G06227 Metronidazole Bezoate Oral B 1 Suspension I.P 100 mg/5ml 30ml Bottle 231 G06230 Norfloxacin DispersibleTablet 100 B 1 mg 232 G06231 Nitazoxanide Tablet 500 mg B 1 233 G06232 Ornidazol Tablet I.P 400mg B 1 234 G06233 Ornidazol Tablet I.P 500mg B 1 235 G06239 Ampicillin and Cloxacillin Capsule B 1 125MG+ 125MG as- EACH CAPSULE CONTAINS AMPICILLIN IP 125MG, CLOXACILLIN SODIUM EQ. TO CLOXACILLIN 125MG 236 G06240 Ampicillin and Cloxacillin Dry Syrup B 1 125MG+ 125MG 30ml Bottle as- AFTER RECONSTITUTION, EACH 5ML CONTAINS : AMPICILLIN TRIHYDRATE IP EQ. TO AMPICILLIN 125MG,CLOXACILLIN SODIUM IP EQ. TO CLOXACILLIN 125MG COLOUR ERYTHROSINE 237 G06256 Fluconazole and Tinidazole Tablet B 1 150MG+ 2G as- EACH KIT CONTAINS 1 TAB FLUCONAZOLE 150 , 2 TAB TINIDAZOLE 1000 MG 238 G06257 Lamivudine And Stavudine Tablet B 1 150mg+ 30mg as- LAMIVUDINE 150 MG STAVUDINE 30 MG 239 G06258 Lamivudine And Stavudine Tablet B 1 150mg+ 40mg as- LAMIVUDINE 150 MG STAVUDINE 40 MG 240 G06259 Pyrimethamine and Sulfadoxine B 1 Tablet 37.5MG+ 750MG as- EACH UNCOATED TABLET CONTAINS : PYRIMETHAMINE IP 37.5MG, SULPHADOXINE IP 750MG 241 G06260 Pyrimethamine and Sulfadoxine B 1 Suspension 12.5MG+ 250MG 10ml Bottle as- EACH 5ML CONTAINS : SULPHADOXINE I.P. 250MG, PYRIMETHAMINE I.P. 12.5MG 242 G07001 Soluble Aspirin Tablet I.P 325 mg B 1 243 G07002 Dihydroergotamine Tablet 1 mg B 1 244 G09001 Bromocriptine Tablet 1.25 mg B 1 245 G09002 Bromocriptine Tablet I.P 2.5mg B 1 246 G09008 Cabregoline Tablet 0.5 mg B 1 247 G10010 Acenocoumarol Tablet 4mg B 1
No:GMSD/KOL/Generic-01 52 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 248 G10013 Menadione Sodium Sulphate Tablet B 1 10 mg 249 G10023 Tranexamic acid Tablet 250mg B 1 250 G10027 Ethamsylate Tablet 250mg B 1 251 G10028 Ethamsylate Tablet 500mg B 1 252 G10035 Protamine Sulphate Tablet B 1 253 G10036 Tranexamic acid Tablet 100mg B 1 254 G11010 Factor IX Complex (Coagulation B 1 Factors II, VII, IX, X) Tablet I.P 1 mg 255 G11011 Factor IX Complex (Coagulation B 1 Factors II, VII, IX, X) Tablet I.P 2mg 256 G11016 H D Fluid Accetate 10 Litre Can B 1 257 G11017 H D Fluid Part A 10 Litre Can B 1 258 G11018 Haemaccel 500ml 500 ml Bottle B 1 259 G11019 Hydroxyethyl starch 10% 500 ml B 1 Bottle 260 G12140 Losartan and Ramipril Tablet B 1 1.25MG+ 50MG as- EACH FILM COATED TAB. CONTAINS: LOSARTAN POTASSIUM 50MG, RAMIPRIL BP 1.25MG EXCIPIENT Q.S. COLOUR TITANIUM DIOXIDE IP 261 G12142 Aspirin and Isosorbide Mononitrate B 1 Capsule 75MG+ 30MG as- EACH CAPSULE CONTAINS: DILUTED ISOSORBIDE MONONITRATE BP EQ TO ISOSORBIDE MONONITRATE 30MG (SUSTAINED RELEASE ), ASPIRIN IP 75MG (ENTERIC COATED) 262 G12143 Aspirin and Isosorbide Mononitrate B 1 Capsule 150MG+ 30MG as- EACH CAPSULE CONTAINS: ISOSORBIDE MONONITRATE BP EQ TO ISOSORBIDE MONONITRATE 30MG (TIME RELEASE PELLETS), ASPIRIN IP 150MG 263 G12144 Aspirin and Isosorbide Mononitrate B 1 Capsule 75MG+ 60MG as- EACH CAPSULE CONTAINS: DILUTED ISOSORBIDE MONONITRATE BP EQ TO ISOSORBIDE MONONITRATE 60MG (SUSTAINED RELEASE ), ASPIRIN IP 75MG (ENTERIC COATED) 264 G12150 Atenolol and Chlorthalidone Tablet B 1 100MG+ 12.5MG as- EACH UNCOATED TABLET CONTAIN CHLORTHALIDONE IP 12.5 MG ATENOLOL IP 50 MG 265 G13001 Compound Benzoic Acid Ointment I.P B 1 30 gm Tube 266 G13002 Miconazole Cream I.P 2% 15 G Tube B 1 267 G13003 Aciclovir Cream 5% 5 G Tube B 1
No:GMSD/KOL/Generic-01 53 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 268 G13004 Framycetin Sulphate Cream 1% 20 G B 1 Tube 269 G13005 Methylrosanilinium Chloride (Gentian B 1 Violet) Aqueous Solution 0.50% 15 ml Bottle 270 G13006 Neomycin and Bacitracin Ointment 5 B 1 mg + 500 IU 5 G Tube 271 G13007 Povidone Iodine Ointment 5% 15 G B 1 Tube 272 G13008 Silver Nitrate Lotion 10% Bottle B 1 273 G13009 Silver Sulphadiazine Sterile Cream 1% B 1 500 G Jar 274 G13010 Silver Sulphadiazine Sterile Cream 1% B 1 25 G Tube 275 G13011 Betamethasone Ointment I.P 0.05% B 1 15 G Tube 276 G13012 Calamine Lotion I.P Lotion 50 ml B 1 Bottle 277 G13013 Zinc Oxide Dusting Powder Dusting B 1 Powder 10 G Bottle 278 G13014 Coal Tar Solution 5% 120 ml Bottle B 1 279 G13015 Dithranol Ointment I.P 2% w/w 15 G B 1 Tube 280 G13016 Glycerin 500ml Solution I.P 500 ml B 1 Bottle 281 G13017 Salicylic Acid Solution 5% 120 ml B 1 Bottle 282 G13018 Benzyl Benzoate Application Emulsion B 1 I.P 25% 500 ml Bottle 283 G13019 Lindane Lotion 100 ml Bottle B 1 284 G13020 Calamine Powder 500 gm 500 G Pkts B 1 285 G13021 Coal tar and salicylic acid Ointment B 1 6%+3% 25G Tube 286 G13022 Distilled Water Can 5 Litre B 1 287 G13023 Heparin and Benzyl Nicotinate B 1 Oinment 50IU/G+ 2mg 20G Tube as- EACH GRAM CONTAINS : HEPARIN SODIUM IP50 IU, BENZYL NICOTINATE 2MG PRESERVATIVE SORBIC ACID IP 1.97 MG 288 G13024 Lanolin Ointment 500 gm 500 G Jar B 1 289 G13025 Permetharin Cream 5% 30G Tube B 1 290 G13026 Permetharin lotion 1% 30ml Bottle B 1 291 G13027 Permetharin lotion 5% 30ml Bottle B 1 292 G13028 Povidone Iodine Cream 5%w/w 15G B 1 Tube 293 G13029 Povidone Iodine mouth wash 2% 100 B 1 ml Bottle 294 G13030 Povidone Iodine solution for scrubing B 1 7.50% 50ml Bottle 295 G13031 Povidone Iodine solution for scrubing B 1 No:GMSD/KOL/Generic-01 54 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 7.50% 100ml Bottle 296 G13032 Salicylic Acid Powder 2% W/W 500G B 1 Container 297 G13033 White Soft Paraffin Jar I.P 500g 500 G B 1 Jar 298 G13036 Cetrimide And Gamma Benzene B 1 Hexachloride Emulsion 0.1W/V+ 1%W/V 100ml Bottle as- GAMMA BENZENE HEXACHLORIDE I.P. 1% W/V CETRIMIDE I.P. 0.1% W/V . IN EMULSION BASE 299 G13045 Hydrocortisone And Miconazole B 1 Nitrate Gel 1%W/W+ 2%W/W 5G Tube as- CONTAINS : MICONAZOLE NITRATE I.P. 2% W/W, HYDROCORTISONE ACETATE I.P. 1% W/W 300 G13057 Ketoconazole And Prepared Coal Tar B 1 Scalp Solution 2%W/V+ 2%W/V 50ml Bottle as- PREPARED COAL TAR IP '66' 2% W/V, KETOCONAZOLE IP 2% W/V, AQUEOUS BASE Q.S. 301 G13058 Ketoconazole And Zinc Pyrithione B 1 Lotion 2%W/V+ 1%W/V 50ml Bottle as- KETOCONAZOLE IP 2% W/V, ZINC PYRITHIONE (ZPTO) 1% W/V,IN SURFACTANT BASE Q.S. 302 G13061 Prepared Coaltar And Salicylic Acid B 1 Solution 1%W/W+ 3%W/W 100ml Bottle as- PREPARED COALTAR IP '66' 1%W/W,SALICYLIC ACID IP 3%W/W AQUEOUS BASE QS 303 G13064 Chlorhexidine Gluconate And Silver B 1 Sulphadiazine Cream 2%+ 1% 500G Jar as- SILVER SULPHADIAZINE USP 1%, CHLORHEXIDINE GLUCONATE0. 2%BP 304 G13065 Dexamethasone Acetate And B 1 Framycetin Sulphate Cream 0.1%W/W+ 1.0%W/W 20G Tube as- EACH GRAM CONTAIN DEXAMETHASONE ACETATE B.P. 0.1% W/W FRAMYCETIN SULPHATE IP 1.0%W/W METHYL PARABEN IP (PRESERVATIVE) 0.08% W/W PROPYL PARABEN IP 0.04% W/W EXCIPIENTS Q 305 G13068 Clobetasone Propionate And B 1 Miconazole Nitrate Cream 0.05%W/W+ 2.0%W/W 15G Tube as- CONTAINS: CLOBETASONE
No:GMSD/KOL/Generic-01 55 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal PROPIONATE BP 0.05% W/W, MICONAZOLE NITRATE IP 2.0% W/W CHLOROCRESOL IP ( AS PRESERVATIVE) 0.1% W/W IN A NON GREASY BASE 306 G13069 Fluocinolone Acetonide And B 1 Miconazole Nitrate Lotion 0.01%W/V+ 2%W/V 10ml Bottle as- MICONAZOLE NITRATE IP 2% W/V, FLUOCINOLONE ACETONIDE IP 0.01% W/V, PRESERVATIVE METHYLPARABEN IP 0.15% W/V, WATER MISCIBLE BASE Q.S. 307 G13070 Fluocinolone Acetonide And B 1 Miconazole Nitrate Ointment 0.01%W/W+ 2%W/W 15G Tube as- MICONAZOLE NITRATE IP 2% W/W, FLUOCINOLONE ACETONIDE IP 0.01% W/W, WATER MISCIBLE BASE Q.S. 308 G14004 Barium Sulphate Suspension I.P 250% B 1 w/v 250 ml Bottle 309 G14005 Barium Sulphate Suspension I.P 100% B 1 w/v 500 ml Bottle 310 G14009 Meglumine Iotroxate Solution 5-8 g B 1 iodine in 100-250 ml Bottle 311 G14010 Propyliodone (Oily) Suspension 500- B 1 600 mg / ml 20 ml Amp 312 G15001 Acriflavin and Glycerin Solution 15 B 1 ml Bottle 313 G15002 Compound Benzoin Tincture I.P 500 B 1 ml Bottle 314 G15003 Cetrimide Solution 20%(conc. For B 1 dilution) 100 ml Bottle 315 G15004 Chlorhexidine Gluconate Solution I.P B 1 5% (conc. for dilution) 100 ml Bottle 316 G15005 Ethyl Alcohol Solution 70% 500 ml B 1 Bottle 317 G15006 Gentian Violet Solution(topical ) B 1 0.50% 100 ml Bottle 318 G15007 Gentian Violet Solution(topical ) B 1 1.00% 100 ml Bottle 319 G15008 Hydrogen Peroxide Solution I.P 6% B 1 500 ml Bottle 320 G15009 Povidone Iodine Solution I.P 5%w/w B 1 500ml Bottle 321 G15010 Povidone Iodine Solution I.P 10%w/w B 1 500ml Bottle 322 G15011 Bleaching Powder Powder Contains B 1 not less than 30 % w/w of available chlorine (as per I.P) 25 KG Drum
No:GMSD/KOL/Generic-01 56 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 323 G15012 Formaldehyde Solution Dilute 34 ml B 1 of formaldehyde solution with water to produce 100 ml (As per I.P) 5 Ltr. Jar 324 G15013 Glutaraldehyde Solution 2% 5 Ltr. Jar B 1 325 G15014 Potassium Permanganate Crystals for B 1 solution 500 G Pkts 326 G15015 Boric acid powder Powder I.P 500 gm B 1 500 G Pkts 327 G15016 Chlorhexidine Gluconate Mouthwash B 1 0.12% 100ml Bottle 328 G15017 Chlorhexidine Gluconate Gel 1.00% B 1 15G Tube 329 G15019 Formaldehyde Tablet 1 gm B 1 330 G15023 Cetrimide And Chlorhexidine B 1 Gluconate Liquid 15.0%W/V+ 7.5%V/V 1Litre Bottle as- COMPOSITION : CHLORHEXIDINE GLUCONATE SOLUTION I.P. 7.5% V/V, STRONG CETRIMIDE SOLUTION B.P. (EQUIVALENT TO) CETRIMIDE IP 15.0% W/V 331 G17003 Omeprazole Capsule I.P 10mg B 1 332 G17005 Omeprazole Capsule 40mg B 1 333 G17007 Ranitidine Tablet I.P 300mg B 1 334 G17010 Domperidone Syrup 1 mg / ml 30 ml B 1 Bottle 335 G17011 Metoclopramide Tablet I.P 10 mg B 1 336 G17012 Metoclopramide Syrup I.P 5 mg / 5ml B 1 30 ml Bottle 337 G17014 Prochlorperazine Tablet I.P 5mg B 1 338 G17015 Prochlorperazine Tablet I.P 25 mg B 1 339 G17016 Promethazine Tablet I.P 10mg B 1 340 G17018 Promethazine Syrup I.P 5mg/5ml 100 B 1 ml Bottle 341 G17021 Dicyclomine Tablet 10mg B 1 342 G17025 Bisacodyl Tablet I.P 5 mg B 1 343 G17026 Bisacodyl Suppositories I.P 5mg B 1 344 G17027 Ispaghula Husk Granules 100G B 1 Bottle 345 G17028 Furazolidone Tablet I.P 100 mg B 1 346 G17029 Furazolidone Oral Suspension I.P 25 B 1 mg / 5 ml 60 ml Bottle 347 G17030 Loperamide Capsule I.P 2 mg B 1 348 G17035 Racecadotril Capsule 100mg B 1 349 G17038 Charcoal Tablet 250mg B 1 350 G17044 lactulose Liquid 10gm/15ml 200ml B 1 Bottle 351 G17045 lactulose Liquid 10gm/15ml 500ml B 1 Bottle 352 G17046 Mefenamic acid and Dicylomine B 1 No:GMSD/KOL/Generic-01 57 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal Tablet 353 G17049 Simethicone and activated charcol B 1 Tablet 80 mg + 250 mg 354 G17053 Sodium Picosulphate Tablet 20mg B 1 355 G17054 Zinc Sulphate Syp Containing B 1 Elemental Zinc Syrup 20mg/5ml 60ml Bottle 356 G17068 Dicyclomine And Ethylmorphine B 1 Tablet 20MG+ 11MG as- EACH UNCOATED TABLET CONTAINS : DICYCLOMINE HYDROCHLORIDE I.P. 20MG, ETHYLMORPHINE HYDROCHLORIDE IP85 11MG 357 G17069 Dicyclomine And Simethicone Drops B 1 10MG+ 40MG 10ml Bottle as- EACH ML CONTAINS:DICYCLOMINE HYDROCHLORIDE IP 10MG, SIMETHICONE IP 40MG 358 G17072 Isopropamide Iodide And B 1 Trifluoperazine Tablet 5MG+ 2MG as- EACH SUGAR COATED TAB. CONTAINS: ISOPROPAMIDE IODIDE USP EQ. TO ISOPROPAMIDE 5MG TRIFLUOPERAZINE HYDROCHLORIDE IP EQ. TO TRIFLUOPERAZINE 2MG, 359 G18010 Hormone Releasing IUD B 1 (Levonorgestrel Releasing IUD ) 360 G18013 Centchroman Tablet 30 mg B 1 361 G18082 Glimepiride and Pioglitazone Tablet B 1 2mg+ 30mg as- EACH UNCOATED TABLET CONTAINS: PIOGLITAZONE HYDROCHLORIDE EQ TO PIOGLITAZONE 30MG, GLIMEPIRIDE USP 2MG 362 G20002 Neostigmine Tablet I.P 15mg B 1 363 G22001 Methylegometrine Tablet I.P 0.125 B 1 mg 364 G22003 Mifepristone Tablet 200 mg B 1 365 G22006 Isoxsuprine Tablet I.P 10 mg B 1 366 G22008 Terbutaline Tablet I.P 2.5 mg B 1 367 G22010 Ritodrine Tablet B 1 368 G22013 Misoprostol Tablet 100 mcg B 1 369 G22014 Misoprostol Tablet 200 mcg B 1 370 G23002 C A P D Fluid 1.50% 1500 ml polybag B 1 371 G23003 Peritoneal Dialysis Fluid I.P 5 lit. 5 B 1 Litre polybag 372 G23004 Peritoneal Dialysis Fluid in 1.7% B 1 Dextrose Fluid 1.70% 1000 ml polybag 373 G23005 Peritoneal Dialysis Fluid in 1.7% B 1 Dextrose Fluid 1.70% 2000 ml
No:GMSD/KOL/Generic-01 58 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal polybag 374 G24001 Chlorpromazine Tablet I.P 25mg B 1 375 G24002 Chlorpromazine Tablet I.P 50mg B 1 376 G24003 Chlorpromazine Tablet I.P 100 mg B 1 377 G24004 Chlorpromazine Syrup 25 mg / 5 ml B 1 100 ml Bottle 378 G24006 Haloperidol Tablet I.P 1.5 mg B 1 379 G24008 Haloperidol Tablet I.P 10mg B 1 380 G24010 Trifluoperazine Tablet I.P 5mg B 1 381 G24011 Trifluoperazine Tablet I.P 10 mg B 1 382 G24015 Imipramine Tablet I.P 75mg B 1 383 G24019 Diazepam Tablet I.P 2 mg B 1 384 G24022 Nitrazepam Tablet I.P 5mg B 1 385 G24023 Nitrazepam Tablet I.P 10 mg B 1 386 G24024 Clomipramine Capsule I.P 10mg B 1 387 G24025 Clomipramine Capsule I.P 25mg B 1 388 G24032 Clozapine Tablet I.P 25mg B 1 389 G24038 Haloperidol Tablet 50 mg B 1 390 G24041 Resperidone Liquid 1mg. 50ml Bottle B 1 391 G24049 Dothiepin Capsules I.P 75mg B 1 392 G24055 Sertraline Tablet 100mg B 1 393 G24057 Trazodone Tablet 50mg B 1 394 G24058 Trazodone Tablet 100 mg B 1 395 G24059 Triclofos oral solution 500mg/5ml B 1 5ml Bottle 396 G25002 Beclomethasone Inhaler I.P 50mcg B 1 200MD Container 397 G25003 Beclomethasone Inhaler I.P 250 mcg B 1 200MD Container 398 G25009 Salbutamol Syrup I.P 2 mg / 5 ml B 1 100ml Bottle 399 G25011 Theophyllin Tablet 100 mg B 1 400 G25012 Theophyllin Tablet 200mg B 1 401 G25013 Codeine Tablet I.P 10mg B 1 402 G25015 Dextromethorphan Hydrobromide B 1 Tablet I.P 30mg 403 G25016 Ipratropium and Salbutamol Inhaler B 1 20mcg + 100mcg 200MD Container 404 G25018 Beclomethasone Inhaler I.P 100mcg B 1 200MD Container 405 G25019 Beclomethasone Inhaler I.P 200mcg B 1 200MD Container 406 G25020 Fluticasone Inhaler I.P 125mcg B 1 120MD Container 407 G25023 Salbutamol Respiratory Solution B 1 2.5mg 2.5ml Amp 408 G25024 Theophyllin Sustained Release Tablet B 1 150mg 409 G25025 Theophyllin Sustained Release Tablet B 1 300mg
No:GMSD/KOL/Generic-01 59 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 410 G25026 Theophyllin Sustained Release Tablet B 1 450mg 411 G25028 Ipratropium and Salbutamol B 1 Respiratory Solution 500mcg + 2.5mg Bottle as- EACH 2.5 ML RESPULES CONTAINS IPRATROPIUM BROMIDE BP 500MCG SALBUTAMOL SULPHATE IP EQ TO SALBUTAMOL IP 2.5MG IN AN ISOTONIC SOLUTION 412 G25029 Salbutamol and Beclomethasone B 1 Inhaler 100mg +50mcg 200MD Container 413 G25032 Salmeterol Inhaler 25mcg 120MD B 1 Container 414 G25033 Formoterol Inhaler 12mcg 120MD B 1 Container 415 G25034 Ipratropium Inhaler 20mcg 120MD B 1 Container 416 G25035 Tiotropium Inhaler 9mcg 120MD B 1 Container 417 G25036 Salbutamol Rotacap 200mcg 30's B 1 Bottle 418 G25037 Salbutamol Rotacap 50mcg 30's B 1 Bottle 419 G25038 Ipratropium Rotacap 40mcg 30,s B 1 Bottle 420 G25039 Formoterol Rotacap 12mcg 30's B 1 Bottle 421 G25041 Beclomethasone Rotacap 100mcg B 1 30's Bottle 422 G25042 Beclomethasone Rotacap 200mcg B 1 30's Bottle 423 G25043 Budesonide Rotacap 200mcg/puff B 1 30's Bottle 424 G25044 Budesonide Rotacap 400mcg/puff B 1 30's Bottle 425 G25045 Mometasone Aqueous Nasal spray B 1 I.P 50mcg 120MD Bottle 426 G25046 Levosalbutamol Syrup 1mg/5ml 100 B 1 ml Bottle 427 G25048 Bromhexine Tablet I.P 8 mg B 1 428 G25050 Budesonide Rotacap 100mcg/puff B 1 30's Bottle 429 G25055 Ipratropium Solution 250 mcg/ml B 1 15ml Bottle 430 G25057 Montelukast Tablet I.P 5mg B 1 431 G25058 Salbutamol Respirator 5mg/ml 15ml B 1 Bottle 432 G25063 Tiotropium Inhaler 20mcg /puff B 1 200MD Container
No:GMSD/KOL/Generic-01 60 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal 433 G25066 Cetirizine And Phenylpropanolamine B 1 Tablet 5MG+ 25MG as- CETIRIZINE 5 MG PHENYLPROPANOLAMINE 25 MG 434 G25073 Fluticasone And Salmeterol Disk B 1 500MCG+ 50MCG Disc of 8 Blisters as- EACH BLISTER CONTAINS: SALMETEROL XINOFOATE EQV.TO SALMETEROL 50MCG, FLUTICASONE PROPIONATE BP 500MCG 435 G25081 Etophylline And Theophyllin Syrup B 1 46.5MG+ 14MG 100ml Bottle as- EACH 5ML CONTAINS ETOFYLLINE BP 46.5MG THEOPHYILLIN IP ANHYDROUS EQ. TO THEOFYLLINE IP HYDRATED 14MG 436 G25086 Budesonide And Formotrol Fumarate B 1 Disk 200MCG+ 12MCG Disc of 8 Blisters as- EACH BLISTER CONTAINS: FORMOTEROL FUMARATE DIHYDRATE EQ. TO FORMOTEROL FUMERATE 12MCG, BUDESONIDE IP 200MCG 437 G25087 Budesonide And Formotrol Fumarate B 1 Disk 400MCG+ 12MCG Disc of 8 Blisters as- EACH BLISTER CONTAINS: FORMOTEROL FUMARATE DIHYDRATE IP EQ. TO FORMOTEROL FUMERATE 12MCG, BUDESONIDE IP 400MCG 438 G25094 Loratadine And Pseudoephedrine B 1 Extended Release Tablet 5MG+ 120MG as- EACH UNCOATED DOUBLE LAYERED TABLET CONTAINS : LORATADINE 5MG, PSEUDOEPHEDRINE HYDROCHLORIDE I.P. 120MG (AS EXTENDED RELEASE) EXCIPIENTS Q. S. 439 G25098 Fluticasone And Salmeterol Inhaler B 1 125MCG+ 25MCG 120MD Container as- SALMETEROL 25 MCG FLUTICASONE 125 MCG SUSPENDED IN PROPELLANT 134 A… QS 440 G25101 Fluticasone And Salmeterol Inhaler B 1 50MCG+ 25MCG 120MD Container as- SALMETEROL 25 MCG FLUTICASONE 50 MCG SUSPENDED IN PROPELLANT 134 A QS 441 G25107 Chlorpheniramine And B 1 Diethylcarbamazine Tablet 1.25MG+ 50MG as- EACH SUGAR COATED
No:GMSD/KOL/Generic-01 61 SlNo vmsno ItemDescription Item Quan Estimated EMD ( Annual Nomenclature+Strength+DosageFor Group tity Required in m+ Specification+ PackSize ) with Rs drawal TABLET CONTAINS: DIETHYLCARBAMAZINE CITRATE IP 50MG CHLORPHENIRAMINE MALEATE IP 1.25MG. EXCIPIENTS QS COLOUR RED OXIDE OF IRON 442 G25108 Chlorpheniramine And B 1 Diethylcarbamazine Tablet 5MG+ 250MG as- EACH FILM COATED TAB CONTAINS DIETHYCARBAMAZINE CITRATE IP 250MG, CHLORPHENIRAMINE MALEATE IP 5MG EXCIPIENTS QS COLOUR TARTRAZINE 443 G26026 Di-sodium hydrogen Citrate Liquid B 1 1.4gm/5ml 100ml Bottle 444 G28007 Natural Bovine Surfactant B 1 (Intratracheal Suspeusion) 8ml Bottle 8 ml Bottle 445 G28009 Nimodipine Tablet 30mg B 1 446 G28011 Sodium Chloride Irrigation Solution I.P B 1 0.9%w/v 200ml polybag 447 G28015 Pentoxyfylline Tablet 1000mg B 1 448 G28016 Potassium Chloride Syrup B 1 1.5gm/15ml 100ml Bottle 449 G28024 Magnesium Sulphate Lotion 50% B 1 w/v/1ml 30ml Bottle Note: Earnest Money Deposit
(i) In the Tender Document where estimated withdrawal is indicated in the Schedule of Requirements-the amount of EMD shall be as indicated against each drug mentioned in Annexure-K in the tender document. The total amount of EMD to be submitted by the bidder will depend on the number of items for which the bidder is quoting the rates. The total EMD amount shall be cumulative value of EMD amount indicated in Annexure-K for the drugs for which the bidder is quoting the rates.
(ii) In the Tender Document where estimated withdrawal is not indicated in the Schedule of Requirements-the amount of EMD shall be a fixed amount of Rs1,00,000(Rupees One Lakh only ) for all the items in the Schedule of Requirements of Tender
No:GMSD/KOL/Generic-01 62 Annexure-L
PRICE SCHEDULE
(This template must not be modified/replaced by the bidder and the same should be submitted after filling the relevant columns shown in white, else the bidder is liable to be rejected for this tender. Bidders are allowed to enter the Bidder Name and Values only)
Tender Inviting Authority: Govt. Medical Store Depot, KolkataTender ID:2015_MHFW_289854
Name of Work: Supply of Generic Drugs
Contract No.GMSD/KOL/Generic-01
Bidder Name:
Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
1 Carbamazepine Syrup 100 mg / 5 ml 50 ml Bottle G05003 A 1
2 Phenytoin Tablet I.P 50mg G05008 A 1
3 Phenytoin Oral Suspension I.P 125mg/5ml 100 ml G05010 A 1 Bottle
4 Sodium Valproate Oral Solution I.P 200 mg / 5 ml 100 G05014 A 1 ml Bottle
5 Oxcarbazepine Tablet I.P 250mg G05021 A 1
6 Zonisamide Tablet 100mg. G05024 A 1
7 Azithromycin Capsule I.P 100 mg G06037 A 1
8 Azithromycin Tablet I.P 250mg G06038 A 1
9 Azithromycin Tablet I.P 500mg G06039 A 1
No:GMSD/KOL/Generic-01 63 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
10 Azithromycin Suspension 100 mg / 5 ml 15ml Bottle G06040 A 1
11 Clarithromycin Tablet I.P 500mg G06045 A 1
12 Clofazimine Capsule I.P 50mg G06073 A 1
13 Clofazimine Capsule I.P 100mg G06074 A 1
14 Aciclovir Tablet I.P 200 mg G06113 A 1
15 Aciclovir Tablet I.P 400mg G06114 A 1
16 Aciclovir Suspension 400 mg / 5 ml 60 ml Bottle G06117 A 1
17 Levofloxacin Tablet 500mg G06166 A 1
18 Cefaclor Capsule I.P 500mg G06171 A 1
19 Cefpodoxime Tablet I.P 100mg G06172 A 1
20 Cefadroxine Tablet 500mg G06174 A 1
21 Clarithromycin Tablet I.P 250mg G06179 A 1
22 Amoxycillin and Cloxacillin Dispersible Tablet 125mg + G06194 A 1 125mg
23 Cefixime Tablet I.P 100mg G06206 A 1
24 Cefixime Oral Suspension 50mg/5ml 30ml Bottle G06207 A 1
25 Clindamycin Capsule I.P 150mg G06210 A 1
26 Clindamycin Capsule I.P 300mg G06211 A 1
27 Amoxycillin and Potassium Clavulanate Dry Syrup G06245 A 1 125MG+ 31.25MG 30ml Bottle as- EACH 5 ML OF RECONSTITUTED SUSPENSION CONTAINS : AMOXICILLIN TRIHYDRATE IP EQUIVALENT TO AMOXICILLIN 125 MG , CLAVULANATE POTASSIUM DILUTED IP EQUIVALENT TO CLAVULANIC ACID 3
No:GMSD/KOL/Generic-01 64 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
28 Amoxycillin and Potassium Clavulanate Dispersible G06247 A 1 Tablet 125MG+ 31.25MG as- EACH UNCOATED DISPERSIBLE TABLET CONTAINS:AMOXYCILLIN TRIHYDRATE IP EQ. TO AMOXYCILLIN 125MG,DILUTED POTASSIUM CLAVULANATE BP EQ. TO CLAVULANIC ACID 31.25MG
29 Ampicillin and Sulbactam Tablet 220MG+ 147MG as- G06251 A 1 EACH FILM COATED TAB CONTAINS SULTAMICILLIN (AS TOSYLATE) 375MG (EQ. TO SULBACTAM 147MG, AMPICILLIN 220MG) COLOUR TITANIUM DIOXIDE
30 Sumatriptan Tablet 25mg G07003 A 1
31 Sumatriptan Tablet 50mg G07004 A 1
32 Rizatriptan Tablet 5mg G07005 A 1
33 Flunarizine Tablet 5mg G07007 A 1
34 Cyclosporine Capsule 10 mg G08002 A 1
35 Cyclosporine Capsule 25 mg, G08003 A 1
36 Cyclosporine Capsule 50mg G08004 A 1
37 Cyclosporine Capsule 100mg G08005 A 1
38 Busulphan Tablet I.P 2 mg G08011 A 1
39 Cyclophosphamide Tablet I.P 50mg G08014 A 1
40 Danazol Capsule I.P 50mg G08020 A 1
41 Danazol Capsule I.P 100mg G08021 A 1
42 Etoposide Capsule I.P 100mg G08024 A 1
43 Flutamide Capsule I.P 250 mg G08026 A 1
44 Melphalan Tablet I.P 2 mg G08032 A 1
45 Melphalan Tablet I.P 5mg G08033 A 1
No:GMSD/KOL/Generic-01 65 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
46 Mercaptopurine Tablet I.P 50 mg G08034 A 1
47 Procarbazine Capsule 50 mg G08040 A 1
48 Raloxifene Tablet 60 mg G08045 A 1
49 Tamoxifen Tablet I.P 10 mg G08046 A 1
50 Ondansetron Tablet I.P 8mg G08050 A 1
51 Ondansetron Oral Solution I.P 2mg/5ml 30 ml Bottle G08052 A 1
52 Imatinib Capsule I.P 100 mg G08054 A 1
53 Hydroxyurea Capsule 500mg G08055 A 1
54 Anastrazole Tablet I.P 1mg G08065 A 1
55 Imatinib Capsule I.P 400 mg G08072 A 1
56 Methotrexate Tablet I.P 7.5mg G08075 A 1
57 Thalidomide Tablet 50mg G08078 A 1
58 Thalidomide Tablet 100mg G08079 A 1
59 Glyceryl Trinitrate Tablet I.P 0.5 mg G12002 A 1
60 Isosorbide Dinitrate Tablet I.P 20 mg G12005 A 1
61 Mexiletine Capsule I.P 50mg G12025 A 1
62 Mexiletine Capsule I.P 150mg G12026 A 1
63 Procainamide Tablet I.P 250 mg G12028 A 1
64 Quinidine Tablet I.P 100mg G12030 A 1
65 Verapamil Tablet I.P 80mg G12032 A 1
66 Chlorthalidone Tablet I.P 25 mg G12039 A 1
67 Chlorthalidone Tablet I.P 50mg G12040 A 1
68 Clonidine Tablet I.P 150mcg G12042 A 1
No:GMSD/KOL/Generic-01 66 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
69 Nifedipine Capsule I.P 5mg G12050 A 1
70 Nifedipine Capsule I.P 10mg G12051 A 1
71 Nifedipine Sustained Release Tablet I.P 10mg G12054 A 1
72 Nifedipine Sustained Release Tablet I.P 20mg G12055 A 1
73 Terazosin Tablet 2mg G12058 A 1
74 Terazosin Tablet 5mg G12059 A 1
75 Digoxin Paediatric Solution I.P 50mcg / ml Bottle G12062 A 1
76 Soluble Aspirin Tablet I.P 100mg as- EACH UNCOATED G12066 A 1 EFFERVESCENT TABLET CONTAINS ACETYL SALICYLIC ACID IP 100MG EFFERVESCENT BASE:QS
77 Atenolol and Chlorothiazide Tablet 50mg + 12.5mg G12072 A 1
78 Enalapril and Amlodipine Tablet 5mg + 5mg as- EACH G12073 A 1 CAPSULE CONTAINS: ENALAPRIL MALEATE IP 5MG , AMLODIPINE BESYLATE BP EQ.TO AMLODIPINE 5MG
79 Labetalol Tablet 10mg G12083 A 1
80 Soluble Aspirin Tablet I.P 350 mg as- EACH UNCOATED G12085 A 1 EFFERVESCENT TABLET CONTAINS ACETYLSALICYLIC ACID IP 350MG, EFFERVESCENT BASE:QS
81 Labetalol Tablet I.P 100mg G12100 A 1
82 Labetalol Tablet I.P 200mg G12101 A 1
83 Clonidine and Hydrochlorothiazide Tablet 100MCG+ G12134 A 1 50MG as- EACH UNCOATED TABLET CONTAINS: CLONIDINE HYDROCHLORIDE IP 100MCG, HYDROCHLOROTHIAZIDE IP 20MG EXCIPIENT Q.S. COLOUR QUINOLINE YELLOW W.S
No:GMSD/KOL/Generic-01 67 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
84 Aspirin and Clopidogrel Enteric Coated Tablet G12137 A 1 162.5MG+ 75MG as- EACH FILM COATED TAB. CONTAINS: CLOPIDOGREL BISULFATE EQ. TO CLOPIDOGREL 75MG, ASPIRIN 162.50MG (AS ENTERIC COATED GRANULES) EXCIPIENTS Q.S.
85 Aspirin and Glycine Tablet 150MG+ 75MG as- ASPIRIN G12156 A 1 + GLYCINE 150MG+75MG
86 Aspirin and Glycine Tablet 75MG+ 37.5MG as- G12157 A 1 ASPIRIN + GLYCINE 75MG+37.5MG
87 Atenolol and Indapamide Tablet 50MG+ 2.5MG as- G12158 A 1 EACH UNCOATED TABLETS CONTAINS ATENOLOL IP 50MG INDAPAMIDE USP 2.5MG
88 Propranolol Capsule 40MG as- EACH CAPSULE G12163 A 1 CONTAINS PROPRANOLOL HYDROCHLORIDE IP 40MG (AS EXTENDED RELEASE PELLETS)
89 Indapamide Sustained Release Tablet 1.5MG as- EACH G12181 A 1 SUSTAINED RELEASEFILM COATED TABLET CONTAINS INDAPAMIDE USP 1.5MG
90 Metoprolol Extended Release Tablet 50MG as- EACH G12186 A 1 EXTENDED RELEASED COATED BILAYER TABLET CONTAINS METOPROLOL SUCCINATE USP 47.50MG EQ. TO METOPROLOL TARTRATE 50MG
91 Metoprolol Extended Release Tablet 25MG as- EACH G12189 A 1 EXTENDED RELEASE FILM COATED TABLETS CONTAINS METOPROLOL SUCCINATE USP 23.75MG EQ. TO METOPROLOL TARTRATE 25MG
92 Hydrochlorothiazide Tablet I.P 25 mg G16003 A 1
93 Frusemide and Amiloride Tablet 20 mg + 5mg G16008 A 1
94 Hydrochlorothiazide and Amiloride Tablet 50mg + 5mg G16009 A 1 as- EACH UNCOATED TABLET CONTAINS:AMILORIDE HCL IP 5MG (AS ANHYDROUS) , ,HYDROCHLORTHIAZIDE IP 50MG
No:GMSD/KOL/Generic-01 68 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
95 Testosterone undecanoate Capsule 40 mg G18006 A 1
96 Ethinyl oestradiol and Levonorgestrel Tablet 0.03 mg G18008 A 1 +0.15 mg
97 Ethinyl oestradiol and Norethisterone Tablet 0.035 mg G18009 A 1 +1mg
98 Ethinyl oestradiol Tablet I.P 0.01mg G18014 A 1
99 Ethinyl oestradiol Tablet I.P 0.05mg G18015 A 1
100 Glibenclamide Tablet I.P 2.5 mg G18016 A 1
101 Metformin Tablet I.P 500mg G18020 A 1
102 Clomifene Tablet I.P 50mg G18023 A 1
103 Clomifene Tablet I.P 100mg G18024 A 1
104 Medroxyprogesterone Acetate Tablet 5mg G18025 A 1
105 Medroxyprogesterone Acetate Tablet 10 mg G18026 A 1
106 Aqueous Iodine Oral Solution 8 mg / 5 ml 100 ml Bottle G18031 A 1
107 Glimepiride and Metformin Tablet 1mg + 500mg G18032 A 1
108 Equine Conjugated Estriol Tablet 0.625mg G18048 A 1
109 Estradiol Gel Single Use Patch 0.10% Sachet G18049 A 1
110 Estradiol Valerate Tablet 1mg G18058 A 1
111 Estriol Cream Cream 0.1%W/W 15G Tube G18059 A 1
112 Ethinyl oestradiol and Drospirenone Tablet G18060 A 1
113 Levothyroxine Tablet 100mcg G18065 A 1
114 Glipizide and Metformin Tablet 2.5MG+ 250MG as- G18078 A 1 EACH UNCOATED TABLET CONTAINS: GLIPIZIDE B.P. 2.5MG, METFORMIN HYDROCHLORIDE I. P. 250MG
No:GMSD/KOL/Generic-01 69 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
115 Glimepiride and Pioglitazone Tablet 2mg+ 15mg as- G18081 A 1 EACH UNCOATED TABLET CONTAINS: PIOGLITAZONE HYDROCHLORIDE EQ TO PIOGLITAZONE 15MG, GLIMEPIRIDE USP 2MG
116 Metformin Sustained Release Tablet 500MG as- EACH G18086 A 1 UNCOATED SUSTAINED RELEASE TABLET CONTAINS METFORMIN HCL IP 500MG
117 Gliclazide Modified Release Tablet 30MG as- EACH G18087 A 1 UNCOATED SCORED MODIFIED RELEASE TABLET CONTAINS GLICLAZIDE BP 30MG
118 Gliclazide Extended Release Tablet 60MG as- EACH G18088 A 1 UNCOATED SCORED EXTENDED RELEASE TABLET CONTANS GLICLAZIDE BP 60MG
119 Halothane 250ml Bottle G01002 B 1
120 Isoflurane Inhalation 100ml Bottle G01003 B 1
121 Nitrous Oxide Inhalation 100 ml Bottle G01006 B 1
122 Oxygen Inhalation G01007 B 1
123 Ethyl Chloride Spray 1% Container G01013 B 1
124 Lignocaine Gel I.P 2% 30 gm Tube G01014 B 1
125 Benzocaine Gel 20% 15 gm Tube G01026 B 1
126 Desflurane Inhalation 250 ml 250ml Bottle G01027 B 1
127 Xylocaine spray 10% 50 ml Bottle G01030 B 1
128 Ibuprofen Tablet I.P 200 mg G02005 B 1
129 Paracetamol Syrup I.P 125mg/5ml 60 ml Bottle G02008 B 1
130 Morphine Tablet 10mg G02011 B 1
131 Pentazocine Tablet I.P 25 mg G02012 B 1
No:GMSD/KOL/Generic-01 70 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
132 Colchicine Tablet I.P 0.5mg G02016 B 1
133 Diacerein Capsule I.P 50mg as- EACH CAPSULE G02024 B 1 CONTAINS DIACEREIN 50MG
134 Diclofenac Ointment 1%w/v 30 gm Tube G02025 B 1
135 Mefenamic Acid Capsule I.P 500mg G02029 B 1
136 Diclofenac Potassium And Tizanidine Tablet 50mg+ G02039 B 1 2mg as- EACH FILM COATED TABLET CONTAINS: TIZANIDINE HYDROCHLORIDE EQ.TO TIZANIDINE 2MG, DICLOFENAC POTASSIUM BP 50MG
137 Dexchlorpheniramine Oral Solution I.P 2mg / 5 ml 100 G03003 B 1 ml Bottle
138 Azelastine Nasal Spray 0.10% 10 ml Container G03011 B 1
139 Fluticasone Nasal spray 100mcg 100MD Container G03012 B 1
140 Cetirizine Syrup 5mg/5ml 60 ml Bottle G03013 B 1
141 Cyproheptadine Tablet I.P 4mg G03014 B 1
142 Fluticasone Nasal spray 50mcg 10 ml/100 md Bottle G03015 B 1
143 Hydroxyzine Syrup 10mg/5ml 100 ml Bottle G03018 B 1
144 Pheniramine Tablet I.P 25 mg G03021 B 1
145 Activated Charcoal Powder I.P 100 G Pkts G04001 B 1
146 Penicillamine Tablet I.P 250 mg G04009 B 1
147 Oral Iron Chelating Agent (Calfer) Tablet 250mg G04013 B 1
148 Activated Charcoal Tablet G04014 B 1
149 Deferasirox Tablet 100 G04015 B 1
150 Deferasirox Tablet 400 G04016 B 1
151 Deferasirox Tablet 250mg G04017 B 1
No:GMSD/KOL/Generic-01 71 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
152 Deferasirox Tablet 500mg G04018 B 1
153 Carbamazepine Sustained Release Tablet 200mg as- G05026 B 1 EACH SUSTAINED RELEASE FILM COATED TABLET CONTAINS CARBAMAZEPINE IP 200MG
154 Albendazole Suspension 200 mg/ 5 ml 10 ml Bottle G06002 B 1
155 Mebendazole Tablet I.P 100 mg G06003 B 1
156 Mebendazole Suspension 100 mg / 5 ml 30 ml Bottle G06004 B 1
157 Pyrantel Pamoate Oral Suspension I.P 250 mg / 5 ml 10 G06007 B 1 ml Bottle
158 Diethylcarbamazine Tablet I.P 50mg G06008 B 1
159 Amoxycillin Oral Suspension I.P 125 mg / 5 ml 60 ml G06010 B 1 Bottle
160 Ampicillin Capsule I.P 250mg G06013 B 1
161 Ampicillin Capsule I.P 500mg G06014 B 1
162 Ampicillin Oral Suspension I.P 125 mg / 5 ml 60 ml G06015 B 1 Bottle
163 Cloxacillin Capsule I.P 250mg G06031 B 1
164 Cloxacillin Capsule I.P 500mg G06032 B 1
165 Cloxacillin Syrup I.P 125 mg / 5 ml 40 ml Bottle G06034 B 1
166 Cephalexin Oral Suspension I.P 125 mg / 5 ml 30ml G06042 B 1 Bottle
167 Chloramphenicol Oral Suspension I.P 125 mg / 5 ml 60 G06047 B 1 ml Bottle
168 Chloramphenicol Capsule I.P 250 mg G06048 B 1
No:GMSD/KOL/Generic-01 72 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
169 Trimethoprim and Sulphamethoxazole Oral Suspension G06055 B 1 I.P 40mg +200 mg / 5 ml 50 ml Bottle as- EACH 5ML CONTAINS: TRIMETHOPRIM IP 40MG, SULPHAMETHOXAZOLE IP 200MG
170 Erythromycin Estolate Suspension 125 mg / 5 ml 60 ml G06057 B 1 Bottle
171 Erythromycin Estolate Tablet 250 mg G06058 B 1
172 Erythromycin Estolate Tablet 500mg G06059 B 1
173 Nalidixic Acid Tablet I.P 250 mg G06063 B 1
174 Roxithromycin Tablet I.P 50 mg G06067 B 1
175 Sulphadiazine Tablet I.P 500 mg G06069 B 1
176 Tetracycline Capsule I.P 250 mg G06070 B 1
177 Dapsone Tablet I.P 50mg G06075 B 1
178 Dapsone Tablet I.P 100mg G06076 B 1
179 Ofloxacin Syrup 50mg/5ml 60 ml Bottle G06086 B 1
180 Clotrimazole Pessaries I.P 100mg G06100 B 1
181 Clotrimazole Pessaries I.P 200mg G06101 B 1
182 Clotrimazole Cream I.P 2% 15G Tube G06102 B 1
183 Fluconazole Tablet I.P 50mg G06103 B 1
184 Fluconazole Tablet I.P 200mg G06106 B 1
185 Flucytosine Capsule I.P 250 mg G06107 B 1
186 Griseofulvin Tablet I.P 125 mg G06108 B 1
187 Ketoconazole Tablet I.P 200 mg G06110 B 1
188 Nystatin Tablet I.P 500,000 IU G06111 B 1
No:GMSD/KOL/Generic-01 73 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
189 Nystatin Pessary I.P 100,000 IU G06112 B 1
190 Didanosine Tablet I.P 250mg G06118 B 1
191 Didanosine Tablet I.P 400mg G06119 B 1
192 Lamivudine Tablet I.P 150 mg G06120 B 1
193 Lamivudine and Zidovudine Tablet I.P 150 mg + 300 G06122 B 1 mg as- LAMIVUDINE 150 MG ZIDOVUDINE 300 MG
194 Stavudine Capsule I.P 15mg G06123 B 1
195 Stavudine Capsule I.P 30mg G06124 B 1
196 Stavudine Capsule I.P 40mg G06125 B 1
197 Zidovudine Tablet I.P 100 mg G06126 B 1
198 Zidovudine Tablet I.P 300mg G06127 B 1
199 Efavirenz Capsule I.P 200mg G06128 B 1
200 Efavirenz Capsule I.P 600mg G06129 B 1
201 Nevirapine Tablet I.P 200 mg G06130 B 1
202 Nevirapine Suspension I.P 50mg / 5ml 100 ml Bottle G06131 B 1
203 Indinavir Capsule I.P 200 mg G06132 B 1
204 Indinavir Capsule I.P 400mg G06133 B 1
205 Nelfinavir Tablet I.P 250mg G06134 B 1
206 Ritonavir Capsule I.P 100 mg G06135 B 1
207 Ritonavir Syrup 400mg/5ml 100 ml Bottle G06136 B 1
208 Saquinavir Tablet I.P 200 mg G06137 B 1
209 Diloxanide Tablet I.P 500mg G06138 B 1
No:GMSD/KOL/Generic-01 74 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
210 Chloroquine Phosphate Tablet I.P approximately G06144 B 1 equivlent to 155mg base
211 Chloroquine Phosphate Suspension I.P 50 mg / 5 ml 60 G06146 B 1 ml Bottle
212 Primaquine Tablet I.P 2.5 mg G06147 B 1
213 Primaquine Tablet I.P 7.5mg G06148 B 1
214 Pyrimethamine Tablet I.P 25mg G06149 B 1
215 Quinine Tablet I.P 300mg G06150 B 1
216 Pyrimethamine and Sulfadoxine Tablet I.P G06152 B 1 25mg+500mg as- EACH UNCOATED TABLET CONTAINS : PYRIMETHAMINE I.P. 25MG, SULPHADOXINE I.P. 500MG
217 Trimethoprim Tablet I.P 100 mg G06154 B 1
218 Famciclobir Tablet 250mg G06187 B 1
219 Dihydroxychloroquine Tablet 200mg G06188 B 1
220 Amoxycillin Dispersible Tablet I.P 125 mg G06199 B 1
221 Artesunate Tablet 50mg G06201 B 1
222 Clotrimazole Lotion 1%w/v 15ml Bottle G06213 B 1
223 Clotrimazole Cream I.P 1%w/w 15G Tube G06214 B 1
224 Clotrimazole and Clindamycin Pessaries 200mg+100mg G06215 B 1
225 Colistin Sulphate Syrup 12.5 mg /5ml 30ml Bottle G06216 B 1
226 Erythromycin stearate Suspension 125mg/5ml 60ml G06217 B 1 Bottle
227 Erythromycin stearate Tablet I.P 250mg G06218 B 1
228 Ivermectin and Albendazol Tablet G06225 B 1
No:GMSD/KOL/Generic-01 75 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
229 Levamisole Tablet I.P 50mg G06226 B 1
230 Metronidazole Bezoate Oral Suspension I.P 100 G06227 B 1 mg/5ml 30ml Bottle
231 Norfloxacin DispersibleTablet 100 mg G06230 B 1
232 Nitazoxanide Tablet 500 mg G06231 B 1
233 Ornidazol Tablet I.P 400mg G06232 B 1
234 Ornidazol Tablet I.P 500mg G06233 B 1
235 Ampicillin and Cloxacillin Capsule 125MG+ 125MG as- G06239 B 1 EACH CAPSULE CONTAINS AMPICILLIN IP 125MG, CLOXACILLIN SODIUM EQ. TO CLOXACILLIN 125MG
236 Ampicillin and Cloxacillin Dry Syrup 125MG+ 125MG G06240 B 1 30ml Bottle as- AFTER RECONSTITUTION, EACH 5ML CONTAINS : AMPICILLIN TRIHYDRATE IP EQ. TO AMPICILLIN 125MG,CLOXACILLIN SODIUM IP EQ. TO CLOXACILLIN 125MG COLOUR ERYTHROSINE
237 Fluconazole and Tinidazole Tablet 150MG+ 2G as- G06256 B 1 EACH KIT CONTAINS 1 TAB FLUCONAZOLE 150 , 2 TAB TINIDAZOLE 1000 MG
238 Lamivudine And Stavudine Tablet 150mg+ 30mg as- G06257 B 1 LAMIVUDINE 150 MG STAVUDINE 30 MG
239 Lamivudine And Stavudine Tablet 150mg+ 40mg as- G06258 B 1 LAMIVUDINE 150 MG STAVUDINE 40 MG
240 Pyrimethamine and Sulfadoxine Tablet 37.5MG+ G06259 B 1 750MG as- EACH UNCOATED TABLET CONTAINS : PYRIMETHAMINE IP 37.5MG, SULPHADOXINE IP 750MG
241 Pyrimethamine and Sulfadoxine Suspension 12.5MG+ G06260 B 1 250MG 10ml Bottle as- EACH 5ML CONTAINS : SULPHADOXINE I.P. 250MG, PYRIMETHAMINE I.P. 12.5MG
No:GMSD/KOL/Generic-01 76 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
242 Soluble Aspirin Tablet I.P 325 mg G07001 B 1
243 Dihydroergotamine Tablet 1 mg G07002 B 1
244 Bromocriptine Tablet 1.25 mg G09001 B 1
245 Bromocriptine Tablet I.P 2.5mg G09002 B 1
246 Cabregoline Tablet 0.5 mg G09008 B 1
247 Acenocoumarol Tablet 4mg G10010 B 1
248 Menadione Sodium Sulphate Tablet 10 mg G10013 B 1
249 Tranexamic acid Tablet 250mg G10023 B 1
250 Ethamsylate Tablet 250mg G10027 B 1
251 Ethamsylate Tablet 500mg G10028 B 1
252 Protamine Sulphate Tablet G10035 B 1
253 Tranexamic acid Tablet 100mg G10036 B 1
254 Factor IX Complex (Coagulation Factors II, VII, IX, X) G11010 B 1 Tablet I.P 1 mg
255 Factor IX Complex (Coagulation Factors II, VII, IX, X) G11011 B 1 Tablet I.P 2mg
256 H D Fluid Accetate 10 Litre Can G11016 B 1
257 H D Fluid Part A 10 Litre Can G11017 B 1
258 Haemaccel 500ml 500 ml Bottle G11018 B 1
259 Hydroxyethyl starch 10% 500 ml Bottle G11019 B 1
260 Losartan and Ramipril Tablet 1.25MG+ 50MG as- G12140 B 1 EACH FILM COATED TAB. CONTAINS: LOSARTAN POTASSIUM 50MG, RAMIPRIL BP 1.25MG EXCIPIENT Q.S. COLOUR TITANIUM DIOXIDE IP
No:GMSD/KOL/Generic-01 77 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
261 Aspirin and Isosorbide Mononitrate Capsule 75MG+ G12142 B 1 30MG as- EACH CAPSULE CONTAINS: DILUTED ISOSORBIDE MONONITRATE BP EQ TO ISOSORBIDE MONONITRATE 30MG (SUSTAINED RELEASE ), ASPIRIN IP 75MG (ENTERIC COATED)
262 Aspirin and Isosorbide Mononitrate Capsule 150MG+ G12143 B 1 30MG as- EACH CAPSULE CONTAINS: ISOSORBIDE MONONITRATE BP EQ TO ISOSORBIDE MONONITRATE 30MG (TIME RELEASE PELLETS), ASPIRIN IP 150MG
263 Aspirin and Isosorbide Mononitrate Capsule 75MG+ G12144 B 1 60MG as- EACH CAPSULE CONTAINS: DILUTED ISOSORBIDE MONONITRATE BP EQ TO ISOSORBIDE MONONITRATE 60MG (SUSTAINED RELEASE ), ASPIRIN IP 75MG (ENTERIC COATED)
264 Atenolol and Chlorthalidone Tablet 100MG+ 12.5MG G12150 B 1 as- EACH UNCOATED TABLET CONTAIN CHLORTHALIDONE IP 12.5 MG ATENOLOL IP 50 MG
265 Compound Benzoic Acid Ointment I.P 30 gm Tube G13001 B 1
266 Miconazole Cream I.P 2% 15 G Tube G13002 B 1
267 Aciclovir Cream 5% 5 G Tube G13003 B 1
268 Framycetin Sulphate Cream 1% 20 G Tube G13004 B 1
269 Methylrosanilinium Chloride (Gentian Violet) Aqueous G13005 B 1 Solution 0.50% 15 ml Bottle
270 Neomycin and Bacitracin Ointment 5 mg + 500 IU 5 G G13006 B 1 Tube
271 Povidone Iodine Ointment 5% 15 G Tube G13007 B 1
272 Silver Nitrate Lotion 10% Bottle G13008 B 1
273 Silver Sulphadiazine Sterile Cream 1% 500 G Jar G13009 B 1
274 Silver Sulphadiazine Sterile Cream 1% 25 G Tube G13010 B 1
No:GMSD/KOL/Generic-01 78 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
275 Betamethasone Ointment I.P 0.05% 15 G Tube G13011 B 1
276 Calamine Lotion I.P Lotion 50 ml Bottle G13012 B 1
277 Zinc Oxide Dusting Powder Dusting Powder 10 G Bottle G13013 B 1
278 Coal Tar Solution 5% 120 ml Bottle G13014 B 1
279 Dithranol Ointment I.P 2% w/w 15 G Tube G13015 B 1
280 Glycerin 500ml Solution I.P 500 ml Bottle G13016 B 1
281 Salicylic Acid Solution 5% 120 ml Bottle G13017 B 1
282 Benzyl Benzoate Application Emulsion I.P 25% 500 ml G13018 B 1 Bottle
283 Lindane Lotion 100 ml Bottle G13019 B 1
284 Calamine Powder 500 gm 500 G Pkts G13020 B 1
285 Coal tar and salicylic acid Ointment 6%+3% 25G Tube G13021 B 1
286 Distilled Water Can 5 Litre G13022 B 1
287 Heparin and Benzyl Nicotinate Oinment 50IU/G+ 2mg G13023 B 1 20G Tube as- EACH GRAM CONTAINS : HEPARIN SODIUM IP50 IU, BENZYL NICOTINATE 2MG PRESERVATIVE SORBIC ACID IP 1.97 MG
288 Lanolin Ointment 500 gm 500 G Jar G13024 B 1
289 Permetharin Cream 5% 30G Tube G13025 B 1
290 Permetharin lotion 1% 30ml Bottle G13026 B 1
291 Permetharin lotion 5% 30ml Bottle G13027 B 1
292 Povidone Iodine Cream 5%w/w 15G Tube G13028 B 1
293 Povidone Iodine mouth wash 2% 100 ml Bottle G13029 B 1
294 Povidone Iodine solution for scrubing 7.50% 50ml G13030 B 1 Bottle
No:GMSD/KOL/Generic-01 79 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
295 Povidone Iodine solution for scrubing 7.50% 100ml G13031 B 1 Bottle
296 Salicylic Acid Powder 2% W/W 500G Container G13032 B 1
297 White Soft Paraffin Jar I.P 500g 500 G Jar G13033 B 1
298 Cetrimide And Gamma Benzene Hexachloride Emulsion G13036 B 1 0.1W/V+ 1%W/V 100ml Bottle as- GAMMA BENZENE HEXACHLORIDE I.P. 1% W/V CETRIMIDE I.P. 0.1% W/V . IN EMULSION BASE
299 Hydrocortisone And Miconazole Nitrate Gel 1%W/W+ G13045 B 1 2%W/W 5G Tube as- CONTAINS : MICONAZOLE NITRATE I.P. 2% W/W, HYDROCORTISONE ACETATE I.P. 1% W/W
300 Ketoconazole And Prepared Coal Tar Scalp Solution G13057 B 1 2%W/V+ 2%W/V 50ml Bottle as- PREPARED COAL TAR IP '66' 2% W/V, KETOCONAZOLE IP 2% W/V, AQUEOUS BASE Q.S.
301 Ketoconazole And Zinc Pyrithione Lotion 2%W/V+ G13058 B 1 1%W/V 50ml Bottle as- KETOCONAZOLE IP 2% W/V, ZINC PYRITHIONE (ZPTO) 1% W/V,IN SURFACTANT BASE Q.S.
302 Prepared Coaltar And Salicylic Acid Solution 1%W/W+ G13061 B 1 3%W/W 100ml Bottle as- PREPARED COALTAR IP '66' 1%W/W,SALICYLIC ACID IP 3%W/W AQUEOUS BASE QS
303 Chlorhexidine Gluconate And Silver Sulphadiazine G13064 B 1 Cream 2%+ 1% 500G Jar as- SILVER SULPHADIAZINE USP 1%, CHLORHEXIDINE GLUCONATE0. 2%BP
304 Dexamethasone Acetate And Framycetin Sulphate G13065 B 1 Cream 0.1%W/W+ 1.0%W/W 20G Tube as- EACH GRAM CONTAIN DEXAMETHASONE ACETATE B.P. 0.1% W/W FRAMYCETIN SULPHATE IP 1.0%W/W METHYL PARABEN IP (PRESERVATIVE) 0.08% W/W PROPYL PARABEN IP 0.04% W/W EXCIPIENTS Q
No:GMSD/KOL/Generic-01 80 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
305 Clobetasone Propionate And Miconazole Nitrate Cream G13068 B 1 0.05%W/W+ 2.0%W/W 15G Tube as- CONTAINS: CLOBETASONE PROPIONATE BP 0.05% W/W, MICONAZOLE NITRATE IP 2.0% W/W CHLOROCRESOL IP ( AS PRESERVATIVE) 0.1% W/W IN A NON GREASY BASE
306 Fluocinolone Acetonide And Miconazole Nitrate Lotion G13069 B 1 0.01%W/V+ 2%W/V 10ml Bottle as- MICONAZOLE NITRATE IP 2% W/V, FLUOCINOLONE ACETONIDE IP 0.01% W/V, PRESERVATIVE METHYLPARABEN IP 0.15% W/V, WATER MISCIBLE BASE Q.S.
307 Fluocinolone Acetonide And Miconazole Nitrate G13070 B 1 Ointment 0.01%W/W+ 2%W/W 15G Tube as- MICONAZOLE NITRATE IP 2% W/W, FLUOCINOLONE ACETONIDE IP 0.01% W/W, WATER MISCIBLE BASE Q.S.
308 Barium Sulphate Suspension I.P 250% w/v 250 ml G14004 B 1 Bottle
309 Barium Sulphate Suspension I.P 100% w/v 500 ml G14005 B 1 Bottle
310 Meglumine Iotroxate Solution 5-8 g iodine in 100-250 G14009 B 1 ml Bottle
311 Propyliodone (Oily) Suspension 500-600 mg / ml 20 ml G14010 B 1 Amp
312 Acriflavin and Glycerin Solution 15 ml Bottle G15001 B 1
313 Compound Benzoin Tincture I.P 500 ml Bottle G15002 B 1
314 Cetrimide Solution 20%(conc. For dilution) 100 ml G15003 B 1 Bottle
315 Chlorhexidine Gluconate Solution I.P 5% (conc. for G15004 B 1 dilution) 100 ml Bottle
316 Ethyl Alcohol Solution 70% 500 ml Bottle G15005 B 1
317 Gentian Violet Solution(topical ) 0.50% 100 ml Bottle G15006 B 1
No:GMSD/KOL/Generic-01 81 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
318 Gentian Violet Solution(topical ) 1.00% 100 ml Bottle G15007 B 1
319 Hydrogen Peroxide Solution I.P 6% 500 ml Bottle G15008 B 1
320 Povidone Iodine Solution I.P 5%w/w 500ml Bottle G15009 B 1
321 Povidone Iodine Solution I.P 10%w/w 500ml Bottle G15010 B 1
322 Bleaching Powder Powder Contains not less than 30 % G15011 B 1 w/w of available chlorine (as per I.P) 25 KG Drum
323 Formaldehyde Solution Dilute 34 ml of formaldehyde G15012 B 1 solution with water to produce 100 ml (As per I.P) 5 Ltr. Jar
324 Glutaraldehyde Solution 2% 5 Ltr. Jar G15013 B 1
325 Potassium Permanganate Crystals for solution 500 G G15014 B 1 Pkts
326 Boric acid powder Powder I.P 500 gm 500 G Pkts G15015 B 1
327 Chlorhexidine Gluconate Mouthwash 0.12% 100ml G15016 B 1 Bottle
328 Chlorhexidine Gluconate Gel 1.00% 15G Tube G15017 B 1
329 Formaldehyde Tablet 1 gm G15019 B 1
330 Cetrimide And Chlorhexidine Gluconate Liquid G15023 B 1 15.0%W/V+ 7.5%V/V 1Litre Bottle as- COMPOSITION : CHLORHEXIDINE GLUCONATE SOLUTION I.P. 7.5% V/V, STRONG CETRIMIDE SOLUTION B.P. (EQUIVALENT TO) CETRIMIDE IP 15.0% W/V
331 Omeprazole Capsule I.P 10mg G17003 B 1
332 Omeprazole Capsule 40mg G17005 B 1
333 Ranitidine Tablet I.P 300mg G17007 B 1
334 Domperidone Syrup 1 mg / ml 30 ml Bottle G17010 B 1
335 Metoclopramide Tablet I.P 10 mg G17011 B 1
No:GMSD/KOL/Generic-01 82 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
336 Metoclopramide Syrup I.P 5 mg / 5ml 30 ml Bottle G17012 B 1
337 Prochlorperazine Tablet I.P 5mg G17014 B 1
338 Prochlorperazine Tablet I.P 25 mg G17015 B 1
339 Promethazine Tablet I.P 10mg G17016 B 1
340 Promethazine Syrup I.P 5mg/5ml 100 ml Bottle G17018 B 1
341 Dicyclomine Tablet 10mg G17021 B 1
342 Bisacodyl Tablet I.P 5 mg G17025 B 1
343 Bisacodyl Suppositories I.P 5mg G17026 B 1
344 Ispaghula Husk Granules 100G Bottle G17027 B 1
345 Furazolidone Tablet I.P 100 mg G17028 B 1
346 Furazolidone Oral Suspension I.P 25 mg / 5 ml 60 ml G17029 B 1 Bottle
347 Loperamide Capsule I.P 2 mg G17030 B 1
348 Racecadotril Capsule 100mg G17035 B 1
349 Charcoal Tablet 250mg G17038 B 1
350 lactulose Liquid 10gm/15ml 200ml Bottle G17044 B 1
351 lactulose Liquid 10gm/15ml 500ml Bottle G17045 B 1
352 Mefenamic acid and Dicylomine Tablet G17046 B 1
353 Simethicone and activated charcol Tablet 80 mg + 250 G17049 B 1 mg
354 Sodium Picosulphate Tablet 20mg G17053 B 1
355 Zinc Sulphate Syp Containing Elemental Zinc Syrup G17054 B 1 20mg/5ml 60ml Bottle
No:GMSD/KOL/Generic-01 83 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
356 Dicyclomine And Ethylmorphine Tablet 20MG+ 11MG G17068 B 1 as- EACH UNCOATED TABLET CONTAINS : DICYCLOMINE HYDROCHLORIDE I.P. 20MG, ETHYLMORPHINE HYDROCHLORIDE IP85 11MG
357 Dicyclomine And Simethicone Drops 10MG+ 40MG G17069 B 1 10ml Bottle as- EACH ML CONTAINS:DICYCLOMINE HYDROCHLORIDE IP 10MG, SIMETHICONE IP 40MG
358 Isopropamide Iodide And Trifluoperazine Tablet 5MG+ G17072 B 1 2MG as- EACH SUGAR COATED TAB. CONTAINS: ISOPROPAMIDE IODIDE USP EQ. TO ISOPROPAMIDE 5MG TRIFLUOPERAZINE HYDROCHLORIDE IP EQ. TO TRIFLUOPERAZINE 2MG,
359 Hormone Releasing IUD (Levonorgestrel Releasing IUD ) G18010 B 1
360 Centchroman Tablet 30 mg G18013 B 1
361 Glimepiride and Pioglitazone Tablet 2mg+ 30mg as- G18082 B 1 EACH UNCOATED TABLET CONTAINS: PIOGLITAZONE HYDROCHLORIDE EQ TO PIOGLITAZONE 30MG, GLIMEPIRIDE USP 2MG
362 Neostigmine Tablet I.P 15mg G20002 B 1
363 Methylegometrine Tablet I.P 0.125 mg G22001 B 1
364 Mifepristone Tablet 200 mg G22003 B 1
365 Isoxsuprine Tablet I.P 10 mg G22006 B 1
366 Terbutaline Tablet I.P 2.5 mg G22008 B 1
367 Ritodrine Tablet G22010 B 1
368 Misoprostol Tablet 100 mcg G22013 B 1
369 Misoprostol Tablet 200 mcg G22014 B 1
370 C A P D Fluid 1.50% 1500 ml polybag G23002 B 1
371 Peritoneal Dialysis Fluid I.P 5 lit. 5 Litre polybag G23003 B 1
No:GMSD/KOL/Generic-01 84 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
372 Peritoneal Dialysis Fluid in 1.7% Dextrose Fluid 1.70% G23004 B 1 1000 ml polybag
373 Peritoneal Dialysis Fluid in 1.7% Dextrose Fluid 1.70% G23005 B 1 2000 ml polybag
374 Chlorpromazine Tablet I.P 25mg G24001 B 1
375 Chlorpromazine Tablet I.P 50mg G24002 B 1
376 Chlorpromazine Tablet I.P 100 mg G24003 B 1
377 Chlorpromazine Syrup 25 mg / 5 ml 100 ml Bottle G24004 B 1
378 Haloperidol Tablet I.P 1.5 mg G24006 B 1
379 Haloperidol Tablet I.P 10mg G24008 B 1
380 Trifluoperazine Tablet I.P 5mg G24010 B 1
381 Trifluoperazine Tablet I.P 10 mg G24011 B 1
382 Imipramine Tablet I.P 75mg G24015 B 1
383 Diazepam Tablet I.P 2 mg G24019 B 1
384 Nitrazepam Tablet I.P 5mg G24022 B 1
385 Nitrazepam Tablet I.P 10 mg G24023 B 1
386 Clomipramine Capsule I.P 10mg G24024 B 1
387 Clomipramine Capsule I.P 25mg G24025 B 1
388 Clozapine Tablet I.P 25mg G24032 B 1
389 Haloperidol Tablet 50 mg G24038 B 1
390 Resperidone Liquid 1mg. 50ml Bottle G24041 B 1
391 Dothiepin Capsules I.P 75mg G24049 B 1
392 Sertraline Tablet 100mg G24055 B 1
No:GMSD/KOL/Generic-01 85 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
393 Trazodone Tablet 50mg G24057 B 1
394 Trazodone Tablet 100 mg G24058 B 1
395 Triclofos oral solution 500mg/5ml 5ml Bottle G24059 B 1
396 Beclomethasone Inhaler I.P 50mcg 200MD Container G25002 B 1
397 Beclomethasone Inhaler I.P 250 mcg 200MD Container G25003 B 1
398 Salbutamol Syrup I.P 2 mg / 5 ml 100ml Bottle G25009 B 1
399 Theophyllin Tablet 100 mg G25011 B 1
400 Theophyllin Tablet 200mg G25012 B 1
401 Codeine Tablet I.P 10mg G25013 B 1
402 Dextromethorphan Hydrobromide Tablet I.P 30mg G25015 B 1
403 Ipratropium and Salbutamol Inhaler 20mcg + 100mcg G25016 B 1 200MD Container
404 Beclomethasone Inhaler I.P 100mcg 200MD Container G25018 B 1
405 Beclomethasone Inhaler I.P 200mcg 200MD Container G25019 B 1
406 Fluticasone Inhaler I.P 125mcg 120MD Container G25020 B 1
407 Salbutamol Respiratory Solution 2.5mg 2.5ml Amp G25023 B 1
408 Theophyllin Sustained Release Tablet 150mg G25024 B 1
409 Theophyllin Sustained Release Tablet 300mg G25025 B 1
410 Theophyllin Sustained Release Tablet 450mg G25026 B 1
411 Ipratropium and Salbutamol Respiratory Solution G25028 B 1 500mcg + 2.5mg Bottle as- EACH 2.5 ML RESPULES CONTAINS IPRATROPIUM BROMIDE BP 500MCG SALBUTAMOL SULPHATE IP EQ TO SALBUTAMOL IP 2.5MG IN AN ISOTONIC SOLUTION
No:GMSD/KOL/Generic-01 86 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
412 Salbutamol and Beclomethasone Inhaler 100mg G25029 B 1 +50mcg 200MD Container
413 Salmeterol Inhaler 25mcg 120MD Container G25032 B 1
414 Formoterol Inhaler 12mcg 120MD Container G25033 B 1
415 Ipratropium Inhaler 20mcg 120MD Container G25034 B 1
416 Tiotropium Inhaler 9mcg 120MD Container G25035 B 1
417 Salbutamol Rotacap 200mcg 30's Bottle G25036 B 1
418 Salbutamol Rotacap 50mcg 30's Bottle G25037 B 1
419 Ipratropium Rotacap 40mcg 30,s Bottle G25038 B 1
420 Formoterol Rotacap 12mcg 30's Bottle G25039 B 1
421 Beclomethasone Rotacap 100mcg 30's Bottle G25041 B 1
422 Beclomethasone Rotacap 200mcg 30's Bottle G25042 B 1
423 Budesonide Rotacap 200mcg/puff 30's Bottle G25043 B 1
424 Budesonide Rotacap 400mcg/puff 30's Bottle G25044 B 1
425 Mometasone Aqueous Nasal spray I.P 50mcg 120MD G25045 B 1 Bottle
426 Levosalbutamol Syrup 1mg/5ml 100 ml Bottle G25046 B 1
427 Bromhexine Tablet I.P 8 mg G25048 B 1
428 Budesonide Rotacap 100mcg/puff 30's Bottle G25050 B 1
429 Ipratropium Solution 250 mcg/ml 15ml Bottle G25055 B 1
430 Montelukast Tablet I.P 5mg G25057 B 1
431 Salbutamol Respirator 5mg/ml 15ml Bottle G25058 B 1
432 Tiotropium Inhaler 20mcg /puff 200MD Container G25063 B 1
No:GMSD/KOL/Generic-01 87 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
433 Cetirizine And Phenylpropanolamine Tablet 5MG+ G25066 B 1 25MG as- CETIRIZINE 5 MG PHENYLPROPANOLAMINE 25 MG
434 Fluticasone And Salmeterol Disk 500MCG+ 50MCG Disc G25073 B 1 of 8 Blisters as- EACH BLISTER CONTAINS: SALMETEROL XINOFOATE EQV.TO SALMETEROL 50MCG, FLUTICASONE PROPIONATE BP 500MCG
435 Etophylline And Theophyllin Syrup 46.5MG+ 14MG G25081 B 1 100ml Bottle as- EACH 5ML CONTAINS ETOFYLLINE BP 46.5MG THEOPHYILLIN IP ANHYDROUS EQ. TO THEOFYLLINE IP HYDRATED 14MG
436 Budesonide And Formotrol Fumarate Disk 200MCG+ G25086 B 1 12MCG Disc of 8 Blisters as- EACH BLISTER CONTAINS: FORMOTEROL FUMARATE DIHYDRATE EQ. TO FORMOTEROL FUMERATE 12MCG, BUDESONIDE IP 200MCG
437 Budesonide And Formotrol Fumarate Disk 400MCG+ G25087 B 1 12MCG Disc of 8 Blisters as- EACH BLISTER CONTAINS: FORMOTEROL FUMARATE DIHYDRATE IP EQ. TO FORMOTEROL FUMERATE 12MCG, BUDESONIDE IP 400MCG
438 Loratadine And Pseudoephedrine Extended Release G25094 B 1 Tablet 5MG+ 120MG as- EACH UNCOATED DOUBLE LAYERED TABLET CONTAINS : LORATADINE 5MG, PSEUDOEPHEDRINE HYDROCHLORIDE I.P. 120MG (AS EXTENDED RELEASE) EXCIPIENTS Q. S.
439 Fluticasone And Salmeterol Inhaler 125MCG+ 25MCG G25098 B 1 120MD Container as- SALMETEROL 25 MCG FLUTICASONE 125 MCG SUSPENDED IN PROPELLANT 134 A… QS
440 Fluticasone And Salmeterol Inhaler 50MCG+ 25MCG G25101 B 1 120MD Container as- SALMETEROL 25 MCG FLUTICASONE 50 MCG SUSPENDED IN PROPELLANT 134 A QS
No:GMSD/KOL/Generic-01 88 Sl. Item Description VMS Item Unit Net Price Per Unit No. No. Group Quantit offered to MSO (Nomenclature + Strength + Dosage Form + y for (Inclusive of all Specification + Pack Size) which Taxes) Rate to (in Rs.) be Quoted
441 Chlorpheniramine And Diethylcarbamazine Tablet G25107 B 1 1.25MG+ 50MG as- EACH SUGAR COATED TABLET CONTAINS: DIETHYLCARBAMAZINE CITRATE IP 50MG CHLORPHENIRAMINE MALEATE IP 1.25MG. EXCIPIENTS QS COLOUR RED OXIDE OF IRON
442 Chlorpheniramine And Diethylcarbamazine Tablet G25108 B 1 5MG+ 250MG as- EACH FILM COATED TAB CONTAINS DIETHYCARBAMAZINE CITRATE IP 250MG, CHLORPHENIRAMINE MALEATE IP 5MG EXCIPIENTS QS COLOUR TARTRAZINE
443 Di-sodium hydrogen Citrate Liquid 1.4gm/5ml 100ml G26026 B 1 Bottle
444 Natural Bovine Surfactant (Intratracheal Suspeusion) G28007 B 1 8ml Bottle 8 ml Bottle
445 Nimodipine Tablet 30mg G28009 B 1
446 Sodium Chloride Irrigation Solution I.P 0.9%w/v 200ml G28011 B 1 polybag
447 Pentoxyfylline Tablet 1000mg G28015 B 1
448 Potassium Chloride Syrup 1.5gm/15ml 100ml Bottle G28016 B 1
449 Magnesium Sulphate Lotion 50% w/v/1ml 30ml Bottle G28024 B 1
No:GMSD/KOL/Generic-01 89